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List of Abbreviations 
 
Amino Acid Codes 
 
 
One-Letter 
Code 
Three-Letter 
Code 
Amino Acid 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
- β-Ala β-Alanine 
- Ahx Aminohexanoic acid 
- Orn Ornithine 
Ac acetyl  Mtt 4-methyltrityl 
ACN acetonitrile  MW molecular weight 
BMP bone morphogenic protein  MyoD myogenic determination 
factor 
Boc tert-butyloxycarbonyl  NES nuclear export signal 
Cbz benzyloxycarbonyl  NLS nuclear localization signal 
CD circular dichroism  NMP N-methyl-2-pyrrolidone 
CDK cyclin-dependent kinase  NMR nuclear magnetic resonance 
CDKI cyclin-dependent kinase 
inhibitor 
 NOESY nuclear Overhauser effect 
spectroscopy 
COSY correlation spectroscopy  Pbf 2,2,4,6,7-
pentamethyldihydro-
benzofuran-5-sulfonyl 
DCM dichloromethane  PG protecting group 
DIC N,N’-diisopropylcarbodiimide  pRb retinoblastoma protein 
DIEA diisopropylethylamine  PS polystyrene 
DMF N,N-dimethylformamide  PyBOP benzotriazol-1-yl-oxytri-
pyrrolidino-phosphonium 
hexafluorophosphate 
EDT ethandithiol  RMSD root mean square deviation 
ESI electrospray ionization  RP-
HPLC 
reverse phase high perfor-
mance liquid chromato-
graphy 
Fmoc fluorenyl-9-methoxycarbonyl  SBE Smad-binding element 
HATU O-(7-azabenzotriazol-1-yl)-
N,N,N',N'-tetramethyluronium 
hexafluorophosphate 
 SPPS solid phase peptide synthesis 
HBTU O-(1-benzotriazolyl)-N,N,N',N'-
tetramethyluroniumhexafluoro-
phosphate 
 TBTU O-(benzotriazol-1-yl)-
N,N,N',N'-tetramethyl-
uronium tetrafluoroborate 
HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
 TFA trifluoroacetic acid 
HLH helix-loop-helix  TFE 2,2,2-trifluorethanol 
HOBt hydroxybenzotriazole  TGF transforming growth factor 
Id inhibitor of DNA binding / 
inhibitor of differentiation 
 TIS triisopropylsilane 
LZ leucine zipper  TMSBr trimethylsilylbromide 
MALDI-
ToF 
Matrix-Assisted-Laser- 
Desorption-Ionization Time of 
Flight 
 TOCSY total correlation spectroscopy
MAPK mitogen-activated protein kinase  tR retention time 
MBHA Methylbenzhydrylamine  Trt trityl 
MMP matrix metalloproteinase  UV ultraviolet 
MS mass spectrometry  VEGF vascular endothelial growth 
factor 
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I Id proteins – key players in cellular processes 
 
I.1 The HLH protein family 
 
The first step in transferring the genetic information to the synthesis of proteins is the 
transcription of DNA to RNA. This process is initiated by proteins, so-called transcription 
factors, which bind to the DNA and thus trigger the transcriptional activation. Typically, these 
are classified on the basis of their DNA-binding domain. Common domains are the leucine 
zipper (LZ), the Helix-Turn-Helix (HTH) motif, the Helix-Loop-Helix (HLH) motif, zinc-
coordinating binding domains and β-scaffolds for minor groove contacts. The more than 240 
proteins containing a HLH motif are grouped in the HLH protein superfamily which is further 
divided into different classes depending on the presence of other domains in addition to the 
HLH domain (Scheme I.1). Class III and IV proteins present a C-terminal LZ, while others 
exhibit a proline-containing basic region (class VI) or a Per-Ant-Sim (PAS) domain (class 
VII). Alternatively, the HLH proteins can also be classified by their DNA binding preferences 
or their phylogenetic similarity1; however, these methods are less commonly used. 
All HLH proteins except those of class V bear an additional basic region adjacent to the HLH 
motif, which enables the formed homo- or heterodimers to bind to specific hexameric DNA 
consensus sequences like the Ephrussi box (E-box) CANNTG, the N-box CACNAG or the Ets 
site GGAA/T, and thus to activate transcription. A special role is played by the class V 
proteins Id1-4 which are the only group lacking the additional basic region but, nevertheless, 
form heterodimers with proteins from the classes I and II, thus preventing the DNA binding of 
the latter. Using this inhibition mechanism, the Id proteins act as regulators of gene 
expression. The involvement of the HLH proteins in a wide range of developmental processes 
like cellular differentiation, lineage commitment, and sex determination renders them 
interesting subjects of research. 
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Scheme I.1. Classification of the HLH proteins by structural and functional characteristics. Adapted from 
Desprez et al.2. (LZ: leucine zipper; b: basic region; PAS: Per-Ant-Sim region). 
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I.2 The Id proteins 
 
The Id proteins were first identified in 1990 by Robert Benezra.3 Thus far four 
mammalian Id proteins, Id1-4, as well as homolog proteins in drosophila (Emc) and in 
xenopus were identified.4-6 Their lengths range from 119 amino acids for Id3 to 161 for Id4, 
which makes them rather small proteins. In humans the four Id proteins are located on 
chromosomes 20q11 (Id1)7, 8, 2p25 (Id2)7, 1p36.1 (Id3)9, 10 and 6p21-22 (Id4)11. Also splicing 
variants like Id1’8 and Id3L12 were observed, but reports about their functional significance 
are scarce. Sequence alignment reveals a potential HLH motif (Figure I.1), thus making them 
eligible to belong to the HLH protein family. As in the other HLH subfamilies, the HLH 
region is the most conserved throughout the Id proteins. Within the HLH motif helix-2 is 
higher conserved than helix-1. The loop region presents the lowest conservation except for the 
N-terminal PxxP sequence which is present in all four Id proteins and is assumed to be crucial 
for their activity.13 
 
 
 HELIX 1 LOOP HELIX 2 
 
Id1 
1 
L 
 
Y 
 
D 
 
M 
5 
N 
 
G 
 
C
 
Y 
 
S 
10 
R 
 
L 
 
K 
 
E 
 
L
15
V
 
P
 
T
 
L
 
P
20
Q
 
N
 
R
 
K
 
V
25  
K
 
V
 
E
 
I
30  
Q 
 
H 
 
V 
 3
I 
5 
D 
 
Y 
 
I 
 
R
 
D
40  
QS L L
Id2 L Y N M N D C Y S K L K E L V P S I P Q N K K V S K M E I L Q H V I D Y I L D L Q
Id3 L D D M N H C Y S R L R E L V P G V P R G T Q L S Q V E I L Q R V I D Y I L D L Q
Id4 Q C D M N D C Y S R L R R L V P T I P P N K K V S K V E I L Q H V I D Y I L D L Q
Figure I.1. Amino acid sequences of the human Id HLH motifs. 
 
 
I.2.1 Mode of action 
 
The Id proteins participate in a wide range of biological events by forming heterodimers 
with other HLH family members. Preferred partners are the ubiquitously expressed E proteins 
(class I) and tissue-specific transcription factors like MyoD or myogenin (class II). As the 
resulting dimers are no longer able to bind to the DNA, the transcriptional activity of these 
bHLH factors is blocked (Scheme I.2). Hence, the Id proteins are referred to as inhibitors of 
DNA binding or, likewise, as inhibitors of differentiation describing the consequence of their 
interaction. As the interaction between the bHLH dimers and the DNA is highly energetic, it 
is unclear how the Id proteins overcome this energy. To disrupt the DNA-dimer complex, a 
widely accepted hypothesis suggests that the Id proteins sequester the fraction of transiently 
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free bHLH proteins shuttling between different chromatin regions, thus preventing their 
reassociation to the chromatin.14 
 
 
Scheme I.2. Inhibition of the activity of bHLH transcription factors by the Id proteins. 
 
 
 
The function of the Id proteins as regulators of bHLH transcription factors can be 
divided into two categories (Scheme I.3). In the one-way type the Id proteins solely work as 
inhibitors, e.g. in neuronal differentiation15, while in the bifurcation type they act both as 
inhibitors and stimulators depending on the type of bHLH factor, e.g. in the natural killer (NK) 
cell development16. 
In addition to bHLH proteins, also non-bHLH proteins were identified as binding 
partners of the Id proteins, thus expanding the range of potential biological implication: pRb 
family proteins, Ets-family proteins18, MIDA119,20, Pax transcription factors21, adenovirus 
E1A protein22, ADD1/SREBP-1c23 and S5a, a subunit of the 26 S proteasome24 (Table I.1). 
As some of these interactions are specific for individual Id family members, it is suggested 
that they are not mediated by the highly conserved HLH motif, but rather by the less 
conserved N- and C-terminal regions. 
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Scheme I.3. Summary of the functions of the Id proteins in vivo.17 
 
 
 
 
Table I.1. Non-HLH protein binding partners of the Id proteins.  
 
Protein Description Binding 
partners 
S5a subunit of the 26 S proteasome Id1 
pRb family cell cycle regulation; as no direct interaction between pRb and Id2 
could be observed, a multiprotein complex is likely to be involved 
in this interaction25 
Id2 
Ets family (Elk-1, 
SAP-1, SAP-2) 
HTH transcription factors; regulation of expression of immediate 
early genes such as c-fos and egr-1 
Id1-3 
MIDA1 two thirds of the MIDA1 N-terminus resemble Zuotin, a Z-DNA 
binding protein; regulation of cell growth 
Id1 
Pax paired-domain transcription factor, involved in several develop-
mental processes 
Id1 > Id2, Id3 
APC/C subunits Apc1, 
Apc5, Apc8/Cdc23 
degradation of cyclins and other key cell cycle regulators Id2 
adenovirus E1A 
proteins 
induce cell proliferation and death, while inhibiting cell diff-
erentiation 
Id1, Id2 
ADD1/SREBP-1c  control the expression of adipocyte genes, involved in lipogenesis Id2, Id3 
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I.2.2 Regulation of the Id proteins 
 
A prerequisite for the involvement of proteins in a wide range of diverse physiological 
processes is their precise regulation in terms of time and location. This is achieved by tissue-
specific expression, a dynamic rate of protein synthesis, time-specific cellular localization and 
degradation. In the following, mechanisms regulating the Id proteins are reviewed. 
 
Expression of the Id proteins 
Tournay et al. identified Id1 as a physiological target for the early response gene Egr-1, 
which is rapidly induced in the absence of new protein synthesis by a variety of stimuli.26 
Downregulation of Id1 expression is mediated by a range of diverse signals like mitogen 
deprivation, vitamin D, granulocyte colony-stimulating factor, retinoic acid and TGFβ. A 
hormonal regulation of the Id proteins can be found in Sertoli cells, where Id1 expression is 
down-regulated by FSH.27 Finally, also activin was shown to suppress Id expression in 
keratinocytes in vivo.28 
 
TGFβ/BMP regulation of Id expression 
Id protein expression was found to be mediated by the TGFβ/BMP signaling pathway. 
Proteins of the TGFβ  (transforming growth factor β) family are signaling molecules that are 
involved in the regulation of important cellular processes like cell growth, differentiation and 
fate determination. Their signals are transferred by the phosphorylated Smad transcription 
factors. A subclass of the TGFβ family is formed by the bone morphogenic proteins (BMPs), 
which repress neuronal and myogenic cell fate. BMPs29, as well as TGFβ itself, were found to 
participate in Id regulation in a cell-specific manner (Scheme I.4). In epithelial or endothelial 
cells BMP stimulation results in Id gene expression mediated by specific regions on the Id 
promoter: two SBE (Smad-binding elements) regions which bind Smad1 and Smad5, and a 
GC-rich region. Although this has only been reported for the Id1 gene31, it is assumed that Id2 
and Id3 regulation are influenced by the same factors. In some epithelial cell lines the TGFβ 
pathway counteracts the BMP upregulation by downregulating the levels of the Id proteins. 
This downregulation is mediated by the synthesis of the transcriptional repressor ATF3 which 
binds to the ATF/CREB site on the Id promoter and thereby blocks Id expression.32 In 
contrast thereto, the response upon TGFβ stimulation in endothelial cells is concentration 
dependent and mediated by the two TGFβ type I receptors Alk1 and Alk5. 
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Scheme I.4. Regulation of Id genes by members of the TGFβ family (adapted from Benezra and coworkers30). 
PAI: Plasminogen activator inhibitor.  
 
 
 
At low TGFβ concentrations, Alk1 signaling leads to the migration and proliferation of the 
cells, while at high TGFβ concentrations these processes are inhibited by Alk5 signaling.33 
Finally, in immune cells Id2 and Id3 expressions are upregulated by TGFβ  resulting in 
sequestration of E2A. 
 
Phosphorylation of the Id proteins 
Another regulation mechanism of the Id protein function is the posttranslational 
phosphorylation. In the late G1 phase of the cell cycle Id2 and Id3 are phosphorylated by 
cyclin-dependent kinase 2 (CDK2), which modulates their activity and binding behavior and 
allows the progression to the next phase of the cell cycle.34,35
 
Degradation of the Id proteins 
The very narrow time-frame of the Id protein functionality is mirrored in their short half 
life time (t1/2 = 0.5-1h), which results from a coordinated interplay of expression and 
ubiquitin-dependent degradation36. While the Id proteins Id1-3 are degraded via the 26 S 
proteasome pathway, Id4 degradation is regulated differently.37 In case of Id1 and Id3, the 
ubiquitin-dependent degradation was reported to be mediated by the recently identified COP9 
signalosome (CSN)38, 39. This was confirmed by the observation of a direct physical 
interaction between the CSN complex and Id3, and the fact that inhibition of the CSN 
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associated kinases triggers the ubiquitin-dependent degradation of Id1 and Id3. Furthermore, 
the interaction with binding partners renders the Id proteins more stable towards degradation, 
as it was shown for Id136 and Id337, 40. In addition, Iavarone et al. reported on a conserved 
destruction box (D-box) motif RxxLxxxN in all Id proteins but Id3 (Table I.2) which triggers 
their degradation by the anaphase-promoting complex (APC/CCdh1).41 
 
Table I.2. Alignment of D-boxes in the Id proteins.41 
Protein D-box Location 
Id1 RAPLSTLN 126-133 
Id2 RTPLTTLN 100-107 
Id4 RTPLTALN 137-144 
 
 
Localization of the Id proteins 
Besides the temporal regulation, the function of the Id proteins also depends on the 
spatial distribution. Depending on the cell type and cell cycle state, the Id proteins are found 
in the nucleus or in the cytoplasm.40, 42, 43 As the Id proteins are relatively small proteins with 
molecular masses in the range from 13 to 18 kDa, passive diffusion is favored as the principal 
way of localization. Nonetheless, also nuclear export signals (NES) were identified in the Id 
proteins which regulate the transport by nuclear pore complexes (Table I.3). While Id1 
exhibits a NES in the second helix, the NES of Id2 is located in the C-terminal region.44 
Although the Id proteins lack defined canonical nuclear localization signals (NLS), it is likely 
that the basic residues present in the HLH domain fulfill the task of nuclear localization as it 
was shown for Id136. For Id3, which lacks a NLS-like sequence, another localization 
mechanism was observed, which can also be imagined for the other Id proteins: by binding to 
the bHLH protein E47 that does possess a NLS region, Id3 is exclusively localized to the 
nucleus.40 
 
Table I.3. NES- and NLS-like sequences of the Id proteins Id1 and Id2. 
 NES Putative NLS 
98 99 100 101 102 103 104 105 106 107 108 109 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91Id1 
V I D Y I R D L Q L E L S R L K E L V P T L P Q N R K V S K
106 107 108 109 110 111 112 113 114 115   
 
Id2 
L N T D I S I L S L   
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I.3  Id in cellular pathways 
 
The eukaryotic cell cycle is composed of a series of events between two cell divisions. 
An important phase is the G1 to S transition, in which the decision upon the further fate of the 
cell is made. As Id1 and Id2 were found to be upregulated during this cell cycle phase45, it 
was first speculated and later proven that they contribute to cell cycle regulation (Scheme I.5). 
 
Scheme I.5. The role of the Id proteins in the cell cycle. 
 
 
 
 
pRb Pathway 
Iavarone et al. reported upon an interaction between Id2 and the tumor suppressor 
protein pRb in U2OS and SAOS-2 cell lines, which alters the pRb function of suppression of 
cell cycle progression.42, 46 However, a direct protein-protein interaction between the small 
pocket domain of pRb and Id2 could not be observed in vitro.25 The pRb activity is indirectly 
regulated by Id1 and Id3, as they lead to decreased expression of p16INK4a by binding to Ets-
family proteins.47, 48 p16INK4a belongs to the INK4a family of CDK inhibitors (CKI) and is a 
potent inhibitor of the CDK4/CDK6/CyclinD complex that mediates the phosphorylation of 
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pRb. The hyperphosphorylated form of pRb does no longer bind the transcription factor E2F, 
thus promoting cell growth. These findings were confirmed by Id1-/- primary mouse 
embryonic fibroblasts which prematurely enter senescence.47 
 
p53 Pathway 
Although p53 is not required for cell cycle progression, it has the crucial function of 
deciding upon the cell fate once DNA damage occurred: either the cell is arrested in the G1 
phase (senescence) or the cell is subjected to apoptosis. The p53 gene is the most frequently 
mutated gene in human cancer (more than 50% of human cancers are associated with a p53 
mutation49), wherein it is responsible for uncontrolled proliferation. The Id proteins are also 
involved in this pathway, as Id1 transfected human keratinocytes were found to impair the 
DNA damage response of the p53 pathway after exposure to a DNA damaging agent.50 
Moreover, Nakajima et al. reported that the suppression of E1A-induced apoptosis by mutated 
p53 is overcome by coexpression with Id proteins.22 
 
MAPK Pathway  
The MAPK (mitogen-activated protein kinase) signaling pathway induces cell 
proliferation upon mitogen stimulation. Key regulators of this pathway are Raf and MEK1/2, 
which are found after Id1 expression.51 In prostate cancer elevated MAPK levels and the 
expression of egr-1 are connected to a poorer outcome. Ling et al. therefore suggested Id1 to 
be a positive upstream regulator of the MAPK signaling pathway. 
 
p21 Pathway 
The ubiquitous class I bHLH protein E2A possesses two inhibitory regions in addition 
to the HLH domain and blocks the G1-S phase transition by activating the transcription of the 
p21Cip1 gene, another CDKI. This process was reported to be regulated by the Id proteins, 
which bind to the E2A protein and block its growth suppression action.52,53
 
Immortalization 
The lifespan of eukaryotic cells is determined by the telomeric DNA ends which are 
shortened with each cell division. After reaching the end of their lifespan, normal cells enter a 
replicative senescence, in which they stop dividing but remain viable. Telomerase is able to 
counteract the telomere shortening. 
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In human keratinocytes Id1 expression was found to increase telomerase activity and thus to 
produce immortalized cells.50 However, these results are challenged by other reports which 
could not establish a link between Id1 expression and increased telomerase activity. Instead of 
an immortalization only a postponed entry in senescence was observed.54 
 
 
I.4 Id in developmental processes 
 
The role of the Id proteins in developmental processes is based on the cellular pathways 
described above. Several studies on animal knockout models elucidated the participation of Id 
proteins in tissue-specific events (Table I.4). 
 
 
Table I.4. Results from studies on Id knockout animals.55 
Deleted Gene Phenotype 
Id1-/- No major abnormalities, elevated TSP-1 expression 
Id2-/- Lack of lymph nodes, NK cells and Peyer’s patches; defects in spermatogenesis; 
loss of Langerhans cells 
Id3-/- Abnormalities in humoral immunity and T cell development 
Id1-/-, Id3-/- Lethal E13.5, vascular defects in forebrain, premature maturation of neurons 
Id1/Id3 loss of single or 
multiple alleles 
Defects in vascularization and growth of tumor xenografts 
Id2-/-, pRb-/- Compensatory resolution of pRb-/- defects in neurogenesis and hematopoiesis, 
rescue of pRb-/- embryonic lethality, but severe muscle loss leads to postnatal 
demise 
 
 
Surprisingly Id1-/- mice did not produce severe abnormalities, while double knockout of Id1 
and Id3 was lethal. This suggests that lack of Id1 can be compensated by Id3, and that Id1 is 
not essential for embryonic development. Furthermore, the Id proteins are involved in the 
terminal differentiation steps of many cell lineages as diverse as myoblasts, T and B cells, 
mammary epithelial cells, oligodendrocytes and dendritic cells.  
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Ids in neurogenesis56 
Astroglia, oligodendrocytes, ependymal and microglia are the four cell types in the 
central nervous system (CNS) responsible for the support and protection of neural cells. 
While Id1 and Id3 are abundantly expressed in proliferating neuroepithelial cells and 
undifferentiated CNS regions, their expression is decreased in the late stage of CNS 
development. This pattern suggests a role in the proliferation of neural precursor cells and in 
the inhibition of cell differentiation. Id2, in contrast, is still expressed in postnatal 
development and adulthood, pointing to a more complex role in neural tissue. Id4, however, is 
only detected in neural tissue during postgastrulational mouse development and was shown to 
be involved in the development of oligodendrocytes.57 In combination with Id2 it is further 
responsible for the timing of oligodendrocyte regulation.17 These processes are mediated by 
Olig1 and Olig2, two class II bHLH proteins which are sequestered by Id2 and Id4, resulting 
in inhibition of oligodendrocyte lineage commitment. As a consequence, astrocyte 
development, which is not dependent on bHLH factors, is enhanced.58 
 
Ids in the digestive system 
Although no potential bHLH binding partners for the Id proteins have yet been 
identified in the oropharyngial cavity and in the esophagus, it is suggested that the Id proteins 
are regulating the cell growth of these lineages. Evidence came from the observation of Id1 
upregulation in esophageal squamous cell carcinoma (SCC). This involvement is assumed to 
be mediated by the APC/β-catenin pathway.59 However, the Id proteins seem not to contribute 
to the homeostasis of the small intestine epithelium. In the pancreas an increased expression 
of Id1 and Id2 was found during the transformation of β-cells into δ-cells associated with the 
activation of the insulin gene. Furthermore, Id expression was shown to inhibit insulin 
production in insulinoma cells. Suggested mechanisms are the inhibition of the cis-regulated 
insulin control element (ICE) and the sequestration of E2A gene products, which bind to HLH 
complexes and the insulin activator factor INSAF. Finally, in the liver Id1 is upregulated 
during the activation and proliferation of hepatocytes. 
 
Ids and thyroid 
Stimulation of thyroid cell growth in vitro led to upregulation of Id1, whereas activation 
of the protein kinase C pathway downregulated Id1.60 With the tissue-specific class II bHLH 
protein Ash-1 (achaete-scute homolog-1) a potential target of Id1 in thyroid was identified.61 
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Ids and the immune system 
The major cellular components of the immune system are the lymphocytes which are 
divided into three major cell types: the natural killer (NK), T and B cells. All these cell types 
emanate from a common, multipotent precursor. Main participants in lymphocyte 
commitment are the ubiquitous E proteins E2A and HEB, and the Id proteins Id2 and Id3. 
While Id2 is involved in cell fate determination to NK cells, as demonstrated in Id2-/- mice16, 
62, Id3 is crucial for the development of T cells. 
Peyer’s patches (PPs) and lymph nodes (LNs) constitute, together with the spleen, the 
secondary lymphoid system. Their development is dependent on the lymphotoxin (LT) 
signaling pathway through the LTβ receptor and is assumedly regulated by Id2, as mice 
deficient in Id2 do not develop PPs and peripheral LNs.62 It is suggested that a yet 
unidentified bHLH factor negatively regulating the differentiation of lymphoid precursor cells 
to LT-expressing cells is repressed by Id2, which allows a normal development of secondary 
lymphoid organs.17 
 
Ids and mammary differentiation 
A contribution of the Id proteins to the differentiation of mammary epithelial cells is 
underlined by the finding that Id1 expression decreased when murine SCp2 cells were 
induced to differentiate in culture, and that constitutive Id1 expression blocked 
differentiation.63 With ITF-2 (class I HLH protein) a potential binding partner for the Id 
proteins in mammary epithelial cells was identified.64 Furthermore, it is suggested that during 
mammary differentiation Id1 acts as an activator rather than as an inhibitor. Studies on Id2 
deficient female mice showed a severe lactation defect, and the mammary glands of Id2-/- 
pregnant mice failed to proliferate and remained immature.65 These results stress the 
importance of Id2 in cell cycle progression of mammary epithelial cells and propose a 
coordinated interplay between Id1 and Id2 during mammary differentiation. 
 
Ids and spermatogenesis 
In the testis the Id family members possess a distinct expression pattern not only in 
spatio-temporal terms, but also in a dynamic subcellular distribution.66 Closer studies have 
only been conducted with Id2 deficient adult mice which show malformed seminiferous 
tubules and a dramatic decrease in mature sperm. Id2 is mainly expressed in Sertoli cells, 
which are formed in fetal and neonatal periods and whose number is constant during 
adulthood, suggesting Id2 participation in their long-term survival. 
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Ids in skin development 
The keratinocytes are the predominant cell type encountered in the epidermis. As the Id 
proteins were found to be expressed in human epidermis and dysregulated in squamous cell 
carcinoma (SCC)67, an Id regulatory role in keratinocyte proliferation and differentiation was 
proposed. In fact, Id1, Id2, and Id3 are downregulated by activin, a member of the TGF-β 
family, which is involved in skin morphogenesis and wound healing.28 The contribution of the 
Id proteins to wound healing was demonstrated by Schaefer et al., who observed the 
upregulation of Id1 upon skin injury. After mediating the conversion from a sessile into a 
mobile keratinocyte alongside its proliferation, the Id1 level is downregulated again.68 The 
influence of the Id proteins on cell motility can also be observed in tumorigenesis, where they 
facilitate tumor propagation. A pathogenic role of Id1 in psoriasis has also been suggested, as 
it was found to be upregulated in lesioned psoriatic skin.69 
 
Ids in myogenesis 
In the course of myogenesis myoblasts are differentiated into myotubes. This process is 
regulated by the highly coordinated interplay of the muscle regulatory factors MyoD, Myf5, 
myogenin, and Mrf4, (class II bHLH proteins) and their binding partners, the ubiquitous E 
proteins (class I) and the Id proteins (class V). The transcription of muscle-specific target 
genes is activated by heterodimers formed between the muscle regulatory factors and the 
ubiquitous E proteins. As Id1 possesses a high binding affinity for the E proteins, it prevents 
the formation of transcription activating dimers by sequestering the E proteins. This inhibition 
is overcome by p204, a p200 family protein, which binds to the Id proteins and also triggers a 
decrease in their level, presumably by shuttling them from the nucleus to the cytoplasm and 
thus accelerating their degradation.70 Indeed, it was reported that in proliferating C2C12 
myoblasts MyoD and Id1 are co-localized in the nucleus, while in differentiated myotubes 
MyoD was located in the nucleus and Id1 in the cytoplasm.71 
 
Ids and angiogenesis 
Angiogenesis, the formation of new blood vessels out of preexisting ones, is an 
important process during development and wound healing. First evidence for a role of the Id 
proteins in angiogenesis was provided by a study on Id1/Id3 double knockout mice which 
suffered from haemorrhage.72 With thrombospondin-1 (TSP-1) a target gene for the 
transcriptional repression by Id1 was identified.73 TSP-1 is a glycoprotein known to be a 
potent inhibitor of in vivo neovascularization and tumorigenesis. Id1 represses these two 
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events by inhibiting the transcription of TSP-1 via a mechanism yet to be identified. Another 
key player in angiogenic events is the vascular endothelial growth factor (VEGF), a heparin-
binding glycoprotein produced by almost every cell type: loss of Id function has been reported 
to lead to decreased VEGF expression.15  
 
 
I.5 Id proteins and cancer 
 
In comparison to normal cells, important cellular pathways are dysregulated in cancer 
cells, resulting in uncontrolled cell division and spreading to adjacent tissue (invasion) as well 
as distant sites (metastasis). As the Id proteins are involved in cellular pathways regulating 
proliferation and differentiation, it was not surprising to find them also contributing to tumor-
related processes. 
 
Ids in tumorigenesis 
Although the Id proteins do not strictly meet the definition of oncogenes and, up to now, 
no tumor-associated defects in the Id genes have been observed, the fact that overexpression 
of the Id genes is mediated by oncogenes like myc, RAS and (EWS)-ETS and affects 
oncogenic pathways emphasizes their importance in tumorigenic events. Elevated levels of 
the Id proteins have been found in a wide range of tumor types (Table I.5), in which they were 
often connected with heightened severity and poor prognosis.74-76 
 
Ids and centrosomes 
Centrosomes are the primary microtubule organizing centers (MTOC) in mitotic and 
post-mitotic cells. They are situated adjacent to the nucleus and are regulators of cell cycle 
progression. Hasskarl et al. showed that a fraction of Id1, but not of the other Id proteins 
localizes to the centrosomes and mitotic spindle poles, and subsequently induces abnormal 
centrosome and centriole numbers.79 These defects in the centrosome duplication presumably 
contribute to genomic instability and tumor formation, as they decrease the accuracy of 
mitotic replication. Furthermore, this property of the Id1 protein could be linked to the 
presence of its N-terminal and HLH regions. 
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Table I.5. Dysregulated expression of Id mRNAs and proteins in primary human tumors.77, 78 
 
Dysregulated Id Tumor type 
Id1, Id3 Glioblastoma, medulloblastoma, neuroblastoma 
Id1, Id2, Id3 Pancreatic cancer 
Id1, Id2, Id3, Id4 Seminoma 
Id1 Medullary thyroid cancer 
Id1, Id2, Id3 Squamous cell carcinoma 
Id1 Breast carcinoma 
Id1 Endometrial cancer 
Id1 Cervical cancer 
Id1 Melanoma 
Id2 Neuroblastoma 
Id1 Hepatocellular carcinoma 
Id1, Id2, Id3 Colorectal adenocarcinoma 
Id1, Id2, Id3 Astrocytic tumor 
Id2 Ewing’s sarcoma 
Id1, Id3 Ovarian tumor 
Id1, Id2 Prostate cancer 
 
 
Ids in cancer progression 
The pivotal events in tumor progression are angiogenesis, tissue invasion, anaplasia and 
proliferation. In all these processes the Id family members were found to be involved. As 
within the Id protein family Id1 contribution was most exhaustively reviewed, the following 
paragraphs will focus on this Id member. 
 
Tumor progression 
The spreading of tumor cells into adjacent or remote regions requires the destruction of 
the basement membrane and the extracellular matrix (ECM) surrounding the cancer cell. In 
vivo studies revealed that high levels of Id are correlated with an upregulation of MMP2, one 
of the matrix metalloproteinases (MMPs) which are known to mediate membrane degradation. 
Indeed, downregulating Id1 expression resulted in a suppression of invasion and metastatic 
ability of breast cancer cells.80, 81 Moreover Id1-/-Id3+/- mice failed to grow tumors, due to the 
poor vascularization of the xenografts.15 
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Tumor angiogenesis 
Prerequisite for tumor progression and metastasis is a sufficient blood supply 
maintained by the formation of new blood vessels in a process called tumor angiogenesis. The 
initiation of angiogenesis in tumors, the so-called “angiogenic switch”, is triggered by the 
upregulation of VEGF that promotes the exponential growth of the tumor. Like in angiogenic 
events during normal development, also here the Id proteins are involved.82 
 
Development of chemotherapeutic drug resistance 
Chemotherapeutic drugs function by inducing apoptosis in cancer cells. A limitation of 
chemotherapy is the emergence of drug resistance which is associated with a more aggressive 
course of the cancer disease and the resistance to further chemotherapy. Responsible for the 
development of chemotherapeutic drug resistance is the deregulation of the Raf-1/MAPK, 
NF-κB and JNK pathways. Based on the fact that Id1 can activate the Raf-1/MAPK and NF-
κB pathways51, 83, a role of Id1 in the development of drug resistance was anticipated. In fact, 
ectopic Id1 expression was able to induce resistance to taxol treatment in prostate and 
nasopharyngeal carcinoma (NPC) cells (Scheme I.6).84, 85  
 
Scheme I.6. The role of the Id1 protein in cancer progression (adapted from Ling et al.88). 
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Furthermore, also an association to doxorubicin and cyclophosphamide resistance was 
reported86 and, more recently, it was shown that high levels of the Id1 protein protect cancer 
cells against the apoptosis pathway initiated by nine different anticancer drugs, suggesting 
that Id1 promotes cell survival by acting as universal antiapoptotic factor.87 These results 
deliver a hypothesis explaining the link between upregulation of the Id proteins and poor 
prognosis and severity of some human cancer types. 
 
Neuroblastoma 
Neuroblastoma is an extracranial cancer striking infants and children. A characteristic of 
this cancer type is the amplification and overexpression of oncogenic N-Myc (neuronal Myc) 
which was shown to be linked to Id2 upregulation.89 Although Perk et al. reported about Id2 
expression as prognostic value for neuroblastoma patients, these results are disputed by other 
working groups.90 
 
Breast cancer91 
High levels of Id1 expression in several breast cancer cell lines are associated with a 
high level of aggressiveness and invasiveness, therefore Id1 could be imagined as potential 
marker for this pathology. Contrarily to Id1, Id2 is downregulated in breast carcinogenesis. 
 
Colon carcinogenesis 
Most colon cancers are caused by mutations in the APC (adenomatous polypsis coli) 
gene and/or β-catenin gene. In these adenomas a similar expression pattern of Id2 and β-
catenin was observed.92 
 
Pancreatic carcinoma 
The Id proteins are implicated in the tumorigenesis of human pancreatic cancer, a highly 
malignant and almost always fatal cancer type.93 Id1-3 localize in tumor cells and duct-like 
cancer cells, while Id1 and Id2 are also found in the transformed cell cytoplasm. Like in other 
cancer types, overexpression of the Id proteins is associated with an enhanced proliferative 
activity and inhibition of differentiation and, therefore, Id1-3 could represent markers of 
pancreatic malignancy. 
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Epithelial cell derived tumors 
Overexpression of the Id protein in an epithelial cell tumor was firstly reported by Tang 
et al., who observed an upregulation of Id1 in Kaposi’s sarcoma (KS), the most common 
neoplasm in AIDS patients. Up to now, the exact mechanism is unclear, but a contribution of 
the latency-associated nuclear antigen (LANA) is undisputed.94 
 
Hormone refractory cancer 
A drawback in the treatment of patients suffering from breast or prostate cancer is that 
the cancers progress to a hormone refractory stage, where they are no longer dependent on 
hormonal stimulation. Hormonal ablation therapy as the main treatment option fails and a 
high mortality rate is associated with these cancer types. Studies conducted by Lin et al. 
showed a loss of estrogen dependency upon ectopic expression of the Id1 protein, suggesting 
that Id1 overexpression is, at least in part, responsible for the development of the hormone 
refractory stage.95 Despite the exact mechanism being unknown, Id1 was identified as a 
downstream target of the androgen receptor.88  
 
 
I.6 The Id proteins as therapeutic targets 
 
Cancer diseases as one of the main causes of death in developed countries fuel the 
constant need for researching novel, reliable anti-tumor therapeutics. The Id proteins represent 
interesting targets for such a purpose, as they are involved in key events not only related to 
tumorigenesis, but also to cancer progression. The main benefit of targeting the Id proteins is 
their differential expression in normal and cancer adult cells. Moreover, studies conducted on 
Id-knockout models showed that already a partial reduction of Id levels leads to reduced 
tumor invasion and metastasis.81 Also, downregulating Id1 could provide an interesting 
strategy to overcome chemotherapeutic drug resistance, a major drawback in cancer 
treatment.87 Another field of research has come up with the recent reports on a connection 
between Id2 expression and neuronal maturation, offering new therapeutic approaches for the 
treatment of patients suffering from neurological pathologies. 
However, given the vast field of events, in which the Id proteins are participating, selectively 
addressing one key domain, while not tampering with other crucial processes, necessitates the 
precise deciphering of the individual physiological and structural preferences of the Id 
proteins.  
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II Scope and objectives 
 
The last decade saw much effort in unraveling the role of the Id proteins in numerous 
physiological events, as diverse as neuronal differentiation, cell cycle control and 
angiogenesis. In contrast thereto, not much is known about the structural features of these 
biomolecules. Recently, we have reported that the HLH motifs of the Id proteins are, as 
predicted by a sequence alignment study, highly helical, while the N-terminal and C-terminal 
regions display no preferred intrinsic conformation. 
The goal of the work presented in the next chapters has been to investigate the structural 
preferences of the Id HLH motifs by using, on one hand, analogs based on modifications of 
the native amino acid sequences or, on the other hand, peptides containing covalently linked 
HLH monomers. The peptides have been synthesized by solid-phase methodology and 
conformationally characterized by circular dichroism (CD) spectroscopy. In case of the Id2 
HLH motif, NMR investigations have also been conducted to provide a more detailed insight 
into the secondary structure. Furthermore, the possibility of using artificial receptors for the 
molecular recognition of the Id HLH motifs has been investigated, providing first hints on 
accessible side chains on the surface of the HLH domain, which might turn out to be useful 
for the development of selective small-molecule modulators of Id homo- and 
heterodimerization.  
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III Modulating the folding of the Id1 HLH domain by sequence 
modifications 
 
Many physiological events are based on protein-protein or protein-ligand interactions. 
The specificity of these processes has to be guaranteed by a uniquely defined protein structure 
which is based on the amino acid sequence, the so-called primary structure, on secondary 
structures like α-helices, β-sheets and turns, and on a complex spatial arrangement of the 
latter elements via intra- or intermolecular interactions, leading to the tertiary or quaternary 
structure, respectively.  
 
 
III.1 Structural preferences of the HLH proteins 
 
A common tertiary/quaternary structural motif found in proteins is the four-helix bundle 
(Figure III.1), which consists of four helices packed together, either in a parallel or an anti-
parallel orientation. 
 
 
                   
MyoD4    cytochrome b5621 T4 lysozyme2 human growth
hormone3 
 
Figure III.1. Four-helix bundle containing proteins. Marked in red are the four-helix bundles. 
 
 
The four-helix bundle occurs in nature either as isolated fold (cytochrome b562) or as a 
domain of a larger protein (T4 lysozyme), but also as the result of interacting polypeptide 
chains (MyoD).5 Proteins containing four-helix folds take part in diverse functions like 
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electron transfer (cytochrome b562), polysaccharide cleavage (T4 lysozyme) and transcription 
activation (MyoD). Moreover, successful studies have been conducted to reproduce this helix 
fold in de novo designed peptides.6 The four-helix bundle also appears in the HLH protein 
family, arising from the dimerization between two HLH domains as the required step for the 
subsequent activation of DNA transcription. Up to now, only a few crystal structures of HLH 
proteins have been obtained, namely the ones of E477, MyoD4 (Figure III.1), Max8 and USF 
(upstream stimulatory factor)9, all showing a parallel, left-handed four-helix bundle upon 
dimerization. 
As no structural information about the Id proteins is available so far, it remains unclear 
if they adopt a structure similar to the one shown by their parent HLH proteins. However, a 
first hint on the conformational properties of the Id proteins is given by the identification of 
heptad repeats (abcdefg) within the amino acid sequence corresponding to their dimerization 
domain. In these heptads, positions a and d are predominantly occupied by hydrophobic 
amino acids, while at the other positions polar residues prevail (Scheme III.1). This pattern is 
found in amphiphilic helices, where a hydrophilic surface is opposite to a hydrophobic one, 
thus allowing the formation of a hydrophobic core upon dimerization, which contributes to 
the overall stabilization of a protein. An indirect evidence for such a folding mechanism in the 
Id protein family came from the observation of Id2 homodimerization in vivo.10 Crucial for 
this dimerization were shown to be the HLH domain, a cysteine residue in the first helix 
(Cys42) and the regions adjacent to the HLH domain. 
 
 
Scheme III.1. Helical wheel representations of Id1 helix-1 (left) and helix-2 (right). Yellow: unpolar residues; 
green: polar, uncharged residues; blue: basic residues; red: acidic residues. 
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The first steps towards a comprehensive, systematic structural characterization of the HLH 
proteins were taken by Chavali et al. who presented a comparative study of several HLH 
proteins, among them the Id proteins, based on the known crystal structures of E47 and 
MyoD.11 A high similarity between all HLH proteins was observed, and the loop region was 
not found to contribute to the dimer formation. The loop region seems to be rather important 
to drive the appropriate spatial orientation of the two helices in the HLH motif. 
Another interesting feature of the HLH proteins is that, despite the high similarity of 
their HLH domains, their individual aggregation behavior differs: the myogenic transcription 
factors myogenin and MyoD (class II) were reported to form both higher order complexes but 
with different average size, being significantly smaller in the case of MyoD (tetramers).12 
However, another report even describes the presence of MyoD micelles consisting of 100 
monomers.13 In contrast thereto, the ubiquitous factor E12 (class I) exists only as a dimer or a 
mixture of monomers and dimers12, while the Id proteins probably oligomerize, as the isolated 
HLH domains were found to form stable tetramers in the concentration range from 20 to 300 
µM.14 The equilibrium between monomeric and oligomeric species might constitute an 
important regulation mechanism for the diverse biological functions of the HLH proteins, as 
only their monomeric forms are able to interact with their binding partners. The reason for the 
different behavior of similar HLH motifs might be found in the hydrophobic core: indeed, it 
was shown that the oligomeric state of a LZ protein can be controlled by mutating residues in 
its hydrophobic core.15 As every HLH protein possesses a more or less unique functional 
profile, it is likely that despite a rather similar overall structure, the specificity of the diverse 
functionalities is governed by subtle, but crucial structural changes within this protein family, 
which also influence the oligomerization behavior. Therefore, to fully understand the 
implication of the structure on the physiological function, it would be necessary to investigate 
each member individually. 
To evaluate the effect of primary structure alterations on the conformational preferences 
of the Id1 HLH domain, in the presented work we synthesized a series of peptide analogs of 
the Id1 HLH motif containing mutations in the loop region as well as the retro-sequence of 
helix-1 (Table III.1). Additionally, analogs bearing substitutions of fully conserved residues 
were prepared. All these analogs were then investigated by CD spectroscopy, providing 
information on the impact of each modification on the overall structure of the Id1 HLH 
region. 
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Table III.1. Sequences of the synthetic Id1 HLH analogs. 
No. Description Sequence 
III.1 Ac-(66-106) Ac-LYDMNGCYSRLKELVPTLPQNRKVSKVEILQHVIDYIRDLQ-NH2
III.2 Ac-[retro66-80, des81]-(66-106) Ac-VLEKLRSYCGNMDYL-TLPQNRKVS-KVEILQHVIDYIRDLQ-NH2
III.3 Ac-[Ahx82-90]-(66-106) Ac-LYDMNGCYSRLKELVP-Ahx-KVEILQHVIDYIRDLQ-NH2
III.4 Ac-[retro66-80, des81, Ahx82-90]-
(66-106) 
Ac-VLEKLRSYCGNMDYL-Ahx-KVEILQHVIDYIRDLQ-NH2
III.5 Ac-[Orn82-90]-(66-106) Ac-LYDMNGCYSRLKELVP-Orn(Ac)-KVEILQHVIDYIRDLQ-NH2
III.6 Ac-[retro66-80, des81, Orn82-90]- 
(66-106) 
Ac-VLEKLRSYCGNMDYL-Orn(Ac)-KVEILQHVIDYIRDLQ-NH2
III.7 Ac-(89-106)-βAlaLys(retro66-80) Ac-VSKVEILQHVIDYIRDLQ-βAlaLys(Ac-VLEKLRSYCGNMDYL)-NH2
III.8 Ac-(89-106)-βAlaLys(66-83) Ac-VSKVEILQHVIDYIRDLQ-βAlaLys(Ac-LYDMNGCYSRLKELVPTL)-NH2
III.9 Ac-(89-106)-βAlaLys Ac-VSKVEILQHVIDYIRDLQ-βAlaLys-NH2
III.10 Ac-[retro69-80, ProGly81-90]- 
(69-103) 
Ac-VLEKLRSYCGNM-PG-KVEILQHVIDYIR-NH2
III.11 Ac-[F73, 101]-(66-106) Ac-LYDMNGCFSRLKELVPTLPQNRKVSKVEILQHVIDFIRDLQ-NH2
III.12 Ac-[F101]-(66-106) Ac-LYDMNGCYSRLKELVPTLPQNRKVSKVEILQHVIDFIRDLQ-NH2
III.13 Ac-[F73]-(66-106) Ac-LYDMNGCFSRLKELVPTLPQNRKVSKVEILQHVIDYIRDLQ-NH2
 
 
 
III.2 Peptide design 
 
III.2.1 Loop surrogates and retro-sequences 
 
To elucidate the importance of interhelical contacts for the stabilization of the Id1 HLH 
fold, peptides containing the native Id1 HLH helices connected by different linkers were 
synthesized (Table III.1). The incorporation of rigid linkers in place of the native nine residue 
long loop should restrict the number of possible orientations of the two helices to each other 
(Scheme III.2). By comparison of the secondary structure elements composition calculated by 
the CONTIN algorithm for each analog out of the CD data with the one of the native Id HLH 
motif, insights into the preferred orientation of the two helices to each other can be gained. 
Another set of peptides containing the same loop surrogates were synthesized, but in these 
peptides the native sequence of helix-1 was inverted (retro-helix-1). 
 
 
 
 
 
 
 34
III  Modulating the folding of the Id1 HLH domain 
Scheme III.2. Loop substitutions and their putative helix-1/helix-2 orientations induced by the used loop 
surrogates. 
 
 
This approach allows the investigation of the influence of the side-chain packing on the 
overall structure. In order to maintain its favored side-chain packing, the peptide is forced to 
change its native helix orientation, as illustrated in Scheme III.3. Obviously, this change will 
be prevented by a rigid linker substituting the more flexible, native loop region. 
 
 
Scheme III.3. Influence of a retro-sequence on the preference for an anti-parallel or parallel conformation. 
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III.2.2 Phenylalanine scan 
 
A number of different interactions are involved in the stabilization of the three-
dimensional structure of peptides and proteins including hydrogen bonds, salt bridges, π-π 
stacking and cation-π interactions. The latter occur between a cationic group like the side-
chains of lysine, arginine, or histidine and the π-face of the aromatic side chains of 
phenylalanine, tyrosine or tryptophan. As the primary sequences of the Id HLH motifs contain 
several basic residues as well as two conserved tyrosine residues, cation-π interactions might 
contribute to the stabilization of both secondary and tertiary structures. The tyrosine side 
chains may be involved in contacts using their phenyl ring (π-π and cation-π interactions) as 
well as their OH group (H-bonds). To investigate the role of the aromatic residues on the 
folding, peptides reproducing the HLH motif of the Id1 protein, but containing substitutions 
of the native tyrosine residues by phenylalanine were synthesized and characterized by CD 
spectroscopy (Table III.1). For the substitutions, positions 73 and 101 were chosen, as these 
positions are assumed to be involved in self, as well as in partner interactions with the HLH 
proteins (Figure III.2).11 Moreover, position 73 is occupied by phenylalanine in many other 
members of the HLH family, including the ubiquitous transcription factors, suggesting a role 
in the regulation of binding specificity. 
 
 
 
Tyr101 Tyr73’ 
Tyr73 Tyr101’
Figure III.2. Top view of the MyoD HLH dimer showing the potential location of the tyrosine positions in the 
hydrophobic core of the Id1 HLH motif. 
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III.3 Results 
 
III.3.1 Loop surrogates 
 
Native HLH motifs 
 
Peptides III.1 and III.2 contain both the native sequence of the Id1 HLH motif, but in 
peptide III.2 the sequence of the N-terminal helix is inverted. As this modification led to a 
dramatically reduced solubility, probably due to strong aggregation, peptide III.2 could only 
be measured at a maximum concentration of 18 µM. Like the native HLH motif (peptide 
III.1), peptide III.2 shows a CD spectrum characteristic for a helical structure, with two 
minima at 222 and 208 nm, respectively, and a maximum below 200 nm (Figure III.3). The 
ratio of the ellipticity of the two minima, R = [Θ]222/[Θ]208, is 1.14, which suggests the 
presence of interacting helices and is even higher than in the native HLH motif (1.07). Also 
the helix content of 54% (corresponding to 21 out of 40 helical amino acids) slightly 
surpasses the one of the native sequence. 
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Figure III.3. CD spectra of peptides III.1 and III.2 in 0.1 M phosphate buffer (pH 7.3). 
 
 
As the only variation between the two peptides is the retro-sequence of the N-terminal helix, 
which should induce an inversion of the helix orientation to guarantee an efficient side-chain 
packing, the fact that the helical character of peptide III.2 not only is maintained, but even 
improved suggests that the peptide backbone underwent a switch to allow a native-like side-
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chain packing, which additionally led to a more favorable orientation of the two helix dipoles 
(Scheme III.3). 
 
Ahx loop containing peptides 
 
Peptides III.3 and III.4 contain an aminohexanoyl (Ahx) unit as a linker (spacer) 
between the two helices of the HLH motif. This loop surrogate should primarily reduce the 
intramolecular interactions between the two helical flanking regions. In peptide III.4 the 
native sequence of the N-terminal helix is inverted, in order to control whether any interhelix 
contact has been suppressed. 
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Figure III.4. CD spectra of peptide III.3 (52 µM, A) and peptide III.4 (45 µM, B) in 0.1 M phosphate buffer 
(pH 7.3). 
 
 
Peptides III.3 and III.4 show CD spectra resembling those of a helix, but display some 
peculiarities (Figure III.4): in case of peptide III.3, the minimum at 208 nm is quite broad and 
the second minimum, usually located at 222 nm in case of a helical structure, is shifted to a 
longer wavelength (Figure III.4A). Moreover, both minima are only moderately intense. In 
case of peptide III.4 the helical character of the CD curve is more pronounced, with the 
characteristic minima at 222 and 208 nm and a maximum below 200 nm. CONTIN analysis 
yields similar helix contents for both analogs: 30% for III.3 and 33% for III.4 (~10 helical 
residues). In addition thereto, also the β-strand, turns and disordered fractions are comparable. 
The poor helix content suggests that the two putative flanking helices are probably not in 
contact with each other, which is also supported by R values lower than 1 (0.7 for peptide 
III.3 and 0.8 for peptide III.4). However, as the presence of the retro-sequence of helix-1 
resulted in a slightly increased helical character in comparison to the native one, residual 
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helix-helix interactions can be presumed. This would correspond to the situation encountered 
for peptide III.2. Nevertheless, the Ahx containing peptide III.4 features a very short and 
rather rigid linker, thus generating a sterical hindrance for the folding of the two helices 
towards each other. Accordingly, the small number of helical residues for both peptides 
supports the presence of a single helical segment, which is likely to be localized within the C-
terminal region that has been previously shown to possess a high intrinsic helix propensity.16  
 
Ornithine loop containing peptides 
 
Peptides III.5 and III.6 contain an ornithine loop in place of the native nine residue long 
loop sequence. Additionally, in peptide III.6 the sequence of the first helix is inverted. The δ-
ornithine linker was chosen, as it could enable the formation of a mirror-image β-turn similar 
to the one observed with a D-prolylglycine unit17; the two helices should thus be able to fold 
towards each other, producing an anti-parallel orientation of the helix dipoles. Both CD 
spectra present two minima at 222 and 208 nm, accompanied by a maximum below 200 nm, 
which are characteristic for a helical structure (Figure III.5). The curve of peptide III.6 
containing the retro helix-1 is moderately superior in intensity, which is illustrated by the 60% 
helix content obtained by the CONTIN analysis opposed to 42% for peptide III.5. This 
implies that in peptide III.5 14 residues out of 32 are in a helical conformation, while in 
peptide III.6 19 helical residues are present. The latter analog displays nearly the same 
number of helical residues as the native HLH motif III.1. By contrast, in comparison to the 
Ahx containing peptides III.3 and III.4, the ornithine containing peptides reveal a clearly 
superior amount of helical structure, which can be explained by the ability of δ-ornithine to 
induce and stabilize a turn-like motif that improves the interaction of the two flanking helices.  
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Figure III.5. CD spectra of peptide III.5 (66 µM, A) and peptide III.6 (65 µM, B) in 0.1 M phosphate buffer 
(pH 7.3). 
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Furthermore, the side-chain packing in peptide III.6, which corresponds to the one obtained 
for a parallel orientation of the two native helices, seems to be favored, as indicated by the 
additional five helical residues compared to peptide III.5. Another striking feature of analogs 
III.5 and III.6 is their reduced β-strand fraction (2%), compared to the one obtained for the 
native HLH motif (11%), which is likely to reflect a change in the oligomerization properties. 
This might also be the reason for the reduced R values found for peptides III.5 and III.6 (0.80 
and 0.83, respectively) with respect to those of the native sequences III.1 and III.2. However, 
the comparison between peptides III.5 and III.6 shows that the inter-helical side-chain 
packing can be assumed to play an important role in stabilizing the first helix, as the non 
optimal packing in peptide III.5 results in a diminished number of helical residues.  
 
β-AlaLys loop containing peptides 
 
In peptides III.7 and III.8 the native loop sequence is replaced by a β-alanyllysine loop. 
This linker should provide the necessary proximity between the two helices to allow them to 
interact with each other. Moreover, a parallel orientation between the two helix dipoles should 
be favored (Scheme III.2C). In peptide III.7 the retro sequence of helix-1 (retro66-80) has been 
introduced to investigate the importance of the side-chain helix packing. By contrast, in 
peptide III.8 the native sequence 66-83 is present, which contains not only helix-1, but also 
residues located at the junction with the loop (P81TL83). Peptide III.9 was obtained as side-
product during the synthesis of peptide III.8, due to the incomplete deprotection of the ε-
amino group of the lysine residue (incomplete Mtt cleavage), and proved to be useful as a 
reference to study the C-terminal helix-2 alone. The CD curves of the three peptides are 
characteristic for a α-helical structure (Figure III.6). CONTIN analysis provided a helical 
fraction of 48% for III.7, 46% for III.8 and 63% for III.9 corresponding to 17 out of 35 or 38 
helical residues for III.7 and III.8, respectively, and to 12 out of 20 helical residues for III.9. 
The R values are as follows: 0.90 for III.7, 0.80 for III.8 and 0.85 for III.9. Interestingly, 
peptide III.9 that lacks the N-terminal helix-1 is still exhibiting a highly helical structure, 
which again confirms the intrinsic helix propensity of the helix-2. However, conjugation of 
the retro or native sequence of helix-1 (peptide III.7 and III.8, respectively) is accompanied 
by an increase in the number of helical residues of about five. 
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Figure III.6. CD spectra of peptide III.7 (53 µM, A), III.8 (50 µM, B) and III.9 (44 µM, C) in 0.1 M phosphate 
buffer (pH 7.3). 
 
 
Based on the behavior of the HLH analogs III.2, III.4 and III.6 described above, a minor 
helicity was expected for the β-AlaLys loop containing peptide III.7, as it was designed to 
yield parallel helix dipoles with consequent anti-parallel side-chain packing, whereas in 
peptide III.8 the helix dipoles as well as the side-chain packing should be parallel. Thereby, it 
should be noted that the two peptides do not contain exactly the same connecting motif 
between the two helices: while peptide III.7 contains just the β-AlaLys moiety, in peptide 
III.8 the first three N-terminal residues of the native loop were included to produce the larger 
motif β-AlaLys(P81TL83). In the last case the presence of a proline might result in an 
increased flexibility of the linker and, consequently, promote the dynamics of the folding. In 
the case of peptide III.7 the loop is shorter but, nevertheless, might still be long enough 
(contrarily to the δ-ornithine loop in peptide III.5) to allow a partially anti-parallel 
juxtaposition of the two helices, which would lead not only to a parallel side-chain packing 
like in peptide III.8, but also to a favorable anti-parallel helix dipole orientation. 
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Prolylglycine loop containing peptide 
 
Peptide III.10 contains a prolylglycine as a surrogate for the native loop sequence, 
which connects the retro sequence of helix-1 to the native sequence of helix-2 (both helices 
were shortened by three residues to evaluate the importance of the helix length). The CD 
curve exhibits the characteristic bands for a helical structure, but slightly blue-shifted, which 
might reflect an additional contribution of turns (Figure III.7). 
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Figure III.7. CD spectrum of peptide III.10 (84 µM) in 0.1 M phosphate buffer (pH 7.3). 
 
 
Accordingly, CONTIN analysis revealed only 25% helicity for peptide III.10, corresponding 
to 7 helical amino acids out of 27, and the ratio helix/turns was 2:1. The low helical content is 
probably due to a combination of negative effects, including the shortening of the helices as 
well as of the loop. 
  
III.3.2 Phenylalanine scan 
 
In peptide III.11 the tyrosines at positions 73 and 101 were substituted by 
phenylalanine. The CD spectra recorded at different peptide concentrations from 46 µM to 
138 µM are superimposable and characterized by minima at 208 nm and 222 nm, indicating 
the presence of a helical structure (Figure III.8). CONTIN analysis of the CD spectrum of the 
46 µM peptide solution reveals 78% helicity, corresponding to 32 helical residues and 
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matching the number of helical residues predicted for the HLH motif by sequence alignment 
and homology studies.11, 18 The ratio R is 0.93. 
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Figure III.8. CD spectra of peptide III.11 at different concentrations in 0.1 M phosphate buffer (pH 7.3). 
 
 
In peptide III.12 only the tyrosine at position 101 in the second helix was replaced with 
phenylalanine. Due to low solubility in phosphate buffer, the peptide could only be measured 
at a concentration of 58 µM. The obtained CD spectrum (Figure III.9) is indicative for a 
helical structure, as it shows the characteristic bands at 208 and 222 nm. CONTIN analysis 
calculated a helicity of 58%, which is clearly reduced compared to peptide III.11. 
Nonetheless, the ratio R is in the same range and accounts for 0.91. 
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Figure III.9. CD spectrum of peptide III.12 at the concentration of 58 µM in 0.1 M phosphate buffer (pH 7.3). 
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Peptide III.13 contains a tyrosine/phenylalanine substitution at position 73 in the first 
helix. Similarly to peptides III.11 and III.12, the obtained CD spectrum is characteristic for a 
helical structure (Figure III.10). The overall helicity is 85%, as calculated by CONTIN 
analysis, representing the highest one obtained for the peptides presented in this study. The 
ratio R is similar to those obtained for peptides III.11-12 and accounts for 0.95. 
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Figure III.10. CD spectra of peptide III.13 at different concentrations in 0.1 M phosphate buffer (pH 7.3). 
 
A superposition of the CD spectra of the three tyrosine-modified peptides III.11-13 with 
the one obtained for the native sequence clearly shows that the replacement of a phenol group 
with a phenyl group leads to an increment in the α-helix content (Figure III.11). 
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Figure III.11. Superposition of the CD spectra of peptides III.1, III.11, III.12 and III.13. 
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III.4 Discussion 
 
Regarding the obtained CD data for the synthesized Id1 HLH peptides containing loop 
variations, it is evident that the overall helicity of the HLH fold does not only stem from 
contributions of the individual helices, but is also based on an interhelical stabilization. This 
stabilization is strongly dependent upon the correct orientation of the two helices towards 
each other, as shown by the conformational preferences of the synthesized loop analogs 
(Table III.2). Peptide III.9, the isolated helix-2, possesses already remarkable helicity, 
confirming our previous structural studies on the isolated helices of the Id HLH motif.16 This 
underlines the hypothesis of helix-2 serving as nucleation seed for the folding of the HLH 
domain. The loop, on the other hand, presumably plays the important role to let the two 
flanking regions approach and juxtapose in a proper way for interactions, which consequently 
results in the formation and/or stabilization of helix-1. 
 
 
Table III.2. Results of the CONTIN analysis for the secondary structure elements composition of the measured 
peptides. n – number of amino acids, nhelical – calculated number of helical amino acids, ntheor – theoretical 
number of helical residues corresponding to those predicted for the HLH motif by sequence alignment, R – ratio 
between the ellipticity minima at 222 nm and 208 nm. 
 
No. c in µM n helix β-strands turns unordered nhelical ntheor R 
III.1 97 41 49% 11% 14% 25% 20 32 1.07 
III.2 18 40 54% 16% 7% 23% 21 31 1.14 
III.3 52 33 30% 14% 21% 36% 10 33 0.70 
III.4 45 32 33% 10% 17% 40% 11 31 0.80 
III.5 66 33 42% 2% 9% 47% 14 32 0.80 
III.6 65 32 60% 2% 11% 27% 19 31 0.83 
III.7 53 35 48% 3% 11% 37% 17 33 0.90 
III.8 50 38 46% 3% 16% 35% 17 36 0.80 
III.9 44 20 63% 2% 10% 25% 12 18 0.85 
III.10 84 27 25% 15% 12% 49% 7 25 0.79 
III.11 46 41 77% 1% 10% 12% 32 32 0.94 
III.12 58 41 64% 0% 8% 28% 26 32 0.91 
III.13 55 41 85% 0% 9% 6% 35 32 0.95 
 
 
The shortest Id HLH analog that showed a number of helical residues close to the one found 
in the native full-length HLH motif is peptide III.6 containing an ornithine loop and the retro 
sequence of helix-1. These modifications should favor an anti-parallel orientation of the helix 
dipoles and a parallel packing of the side chains. Compared thereto, in peptide III.5, the 
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ornithine analog presenting the native sequence of helix-1, the amount of unordered structure 
is remarkably increased at the expense of the helix content. Taken together, these results 
suggest the preference for a parallel helix side-chain packing. Peptides III.7 and III.8, the β-
AlaLys-loop containing analogs, should prefer a parallel helix orientation, resulting in an anti-
parallel side-chain packing for peptide III.7, while in a parallel one for peptide III.8. 
Unexpectedly, the two peptides displayed a similar structural composition, which can be 
explained by the fact that the putative parallel orientation could be converted into an anti-
parallel one. A similar behavior was observed in case of peptides III.1 and III.2 (Scheme 
III.3), in which the modification of the native HLH sequence by inverting helix-1 showed 
almost no effect on the helix content. Interestingly, by comparing peptide III.8 with peptide 
III.6, the superior helicity of the latter might reflect a positive contribution of the anti-parallel 
alignment of the helix dipoles. 
The lowest amount of helicity was obtained for peptides III.3-4, containing the Ahx moiety, 
and for peptide III.10, containing the PG dipeptide. This suggests that the introduction of 
short elements which do not elicit the possibility of the two flanking regions to get into 
proximity is highly unfavorable, thus confirming the importance of interhelical contacts.  
Most remarkably, the peptides containing tyrosine-phenylalanine substitutions showed 
an increase in helicity compared to the native HLH motif, suggesting that the phenylalanine 
residues are able to increase the stabilization of the structure, presumably by improving the 
packing of the hydrophobic core. As Chavali et al. reported, the modified positions 73 and 
101 are found at the junction of the two helices and are assumedly involved in self as well as 
in partner interactions.11 These interactions are likely to be mediated by π-π or cation-π 
interactions which are improved after substitution with phenylalanine, according to the reports 
by Pletneva et al., who determined a better cation-π binding propensity for phenylalanine 
compared to tyrosine.19 The highest stabilization was obtained for peptide III.13, which bears 
a Phe → Tyr substitution at position 73. The substitution at position 101 does not seem to be 
equally favored, as both the Phe101 containing peptides III.11 and III.12 showed a reduced 
helicity compared to analog III.13. This might suggest a superior role of position 73 in 
stabilizing the hydrophobic core of the fold. Moreover, all three Phe → Tyr analogs feature 
reduced interhelical interactions, as indicated by R values < 1. This might be related to the 
modified hydrophobicity of the core, which might modulate the oligomerization behavior, as 
also observed by Harbury et al. for another protein system.15 
Furthermore, by comparing the obtained R values it can be speculated that this dichroic 
parameter presents an indicator of aggregation tendency, as the property of analog III.2 to 
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aggregate already at very low concentrations was reflected by the highest R value obtained 
(1.14). Most of the other analogs exhibited better solubility and were characterized by R 
values lower than 1. 
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IV Structural preferences of the Id1 HLH dimer 
 
IV.1 Introduction 
 
Disulfide bonds play a crucial role in the tertiary and quaternary structure of proteins.1 
By restraining the conformational freedom of peptides and proteins, they contribute 
considerably to the stabilization of biologically active conformations. Furthermore, 
intramolecular disulfide bridges can be valuable tools for introducing a conformational 
constraint in chemically synthesized peptides. Another widely used application of the 
disulfide bond is the formation of covalent dimers: one example being the covalently linked 
MyoD homodimer, which was obtained by oxidation of the single, native cysteine residue 
located in the C-terminal helix-2. This oxidized dimer was then used to study the solution 
structure of MyoD by NMR spectroscopy2, as strong aggregation of the reduced form caused 
by formation of higher order oligomers hindered a reasonable NMR investigation. 
Intermolecular disulfide bridging has also been applied for the stabilization of peptidic β-
helices3 or coiled coils in the HIV gp41 protein4. Recently, Gellman and coworkers used 
cysteine bridges to elucidate the preferred helical orientation of a de novo designed peptide.5 
For this purpose, the peptides of interest were modified by introduction of an N-terminal 
cysteine containing moiety and subjected to heterodimerization by thiol oxidation. A 
following thiol exchange experiment between the heterodimers and different thiol containing 
peptides allowed the identification of the preferred helical coiled coil. 
We considered a similar approach to be useful to gain information about the Id1 HLH 
domain, whose structural preferences are not fully understood yet. The approach is based on 
the synthesis of peptides containing GGC moieties attached either to the N-terminal (peptide 
IV.1) or the C-terminal end (peptide IV.2) of the native HLH motif. These peptides were 
subsequently oxidized to form disulfide bridged homodimers (Table IV.1).  
  
Table IV.1. Amino acid sequences of the synthetic Id1 HLH analogs used for dimerization and thiol exchange 
studies. 
No. Description Sequence 
IV.1 Ac-CGG-[S72]-(66-106)-GGG Ac-CGG-LYDMNGSYSRLKELV-PTLPQNRKVS-KVEILQHVIDYIRDLQ-GGG-NH2
IV.2 Ac-[S72]-(66-106)-GGC Ac-LYDMNGSYSRLKELV-PTLPQNRKVS-KVEILQHVIDYIRDLQ-GGC-NH2
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A mixture of the two homodimers was then subjected to conditions allowing for a thiol 
exchange, through which both homo- and heterodimers might be formed. The preference for 
either a homo- or heterodimer should deliver insight into the helix packing and orientation of 
the Id1 HLH dimer. 
 
 
IV.2 Peptide design 
 
Two analogs of the native Id1 HLH motif were synthesized by SPPS: peptide IV.1 bears 
an additional CGG moiety for disulfide bridging at the N-terminus of the domain, whereas 
peptide IV.2 bears this moiety at the C-terminus. Moreover, peptide IV.1 contains a GGG 
moiety at the C-terminus to facilitate the identification of potential heterodimers with peptide 
IV.2 by mass spectrometry. The cysteines to be oxidized were separated by two glycines from 
the respective helices to guarantee a sufficient flexibility of the covalent linkage in respect to 
the native motif and to prevent a strong structural impact on the folding of the HLH motif in 
the dimer. Moreover, in both peptides the native cysteine at position 72 was substituted by 
serine to prevent the formation of undesired oxidation products. Oxidation of these peptides 
should generate covalently linked homodimers, in which the helices adjacent to the disulfide 
bridge adopt a parallel orientation. The mixing of the two oxidized peptides IV.1OX and 
IV.2OX under conditions that allow a rearrangement of the disulfide bridge could, however, 
produce the mixed dimer displaying an antiparallel arrangement (Scheme IV.1), thus 
providing information about the preferred helix orientation. 
 
Scheme IV.1. Thiol exchange assay. GSH – reduced glutathione; GSSG – oxidized glutathione. 
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As appropriate mixture for the thiol exchange a solution containing a glutathione redox buffer 
(the oxidized and reduced species of glutathione) in a slightly basic buffered solution (0.1 M 
ammonium carbonate at pH ~ 8) was prepared. The oxidations of the monomeric peptides, as 
well as the thiol exchange assay, were monitored by analytical HPLC and mass spectrometry. 
 
 
IV.3 Results 
 
IV.3.1 Formation of the oxidized homodimers 
 
The synthetically prepared peptides IV.1 and IV.2 were dissolved in ammonium 
carbonate (pH ~ 8) at the concentration of 1 mg mL-1 and subjected to air oxidation, in order 
to produce the corresponding covalently linked homodimers IV.1OX and IV.2OX. The 
disulfide bond formation was monitored by HPLC over 72 h. However, already after 24 h the 
HPLC peak of the reduced monomer disappeared and a new peak corresponding to the 
oxidized peptide emerged at a higher retention time (Figure IV.1). The fact that the oxidation 
reaction ran smoothly and almost to completeness suggests that the formed disulfide bridge 
does not impose an unfavorable constraint to the dimer. 
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Figure IV.1. Monitoring of the air oxidation of peptides IV.1 (left) and IV.2 (right) by HPLC. The solid line 
represents the HPLC of an aliquot taken immediately after dissolving the peptide in ammonium carbonate buffer. 
 
 
After 72 h, the peptides were lyophilized and the presence of the oxidized species was 
additionally confirmed by mass spectrometry (Table IV.2). 
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Table IV.2. Mass characterization of the lyophilized homodimers IV.1OX and IV.2OX. 
 MWmon, calc (Da) MWmon, found (Da) MWdimer, calc (Da) MWdimer, found (Da) 
peptide IV.1 5303.1 5299.0 10604.3 10613 
peptide IV.2 5132.0 5132.7 10262.0 10262 
 
 
IV.3.2 Thiol exchange assay 
 
To probe for selectivity towards one distinct orientation, the two homodimers of 
peptides IV.1 and IV.2 were mixed under conditions that allow a thiol exchange assay. 
Therefore, an equimolar mixture of the two homodimers in ammonium carbonate buffer (pH 
~ 8) containing reduced and oxidized glutathione in a 1:2 ratio was prepared. Already in the 
first aliquot, taken immediately after the start of the thiol exchange assay, mass measurements 
showed the reduced species of IV.1 and IV.2, as well as their glutathione adducts, as 
indicated by the masses of the monomers plus 307 Da. The corresponding HPLC profile 
showed a broad peak at 18.75 min preceded and followed by shoulders at 18.5 min and 19.2 
min, respectively. By comparison of the retention times, the two shoulders were assigned to 
the homodimers IV.2OX and IV.1OX, respectively, whereas the central peak presumably 
corresponds to the glutathione adducts of the reduced peptides (Figure IV.2).  
 
 
18 19 20 21 22 23 24 25 26 
Time (min)
IV.1OX IV.2OX
Figure IV.2. HPLC runs of aliquots of the thiol exchange mixture taken at 0 h, 4.5 h, 22 h and 46 h (from top to 
bottom). 
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After 4.5 h and 22 h, the shoulder of IV.1OX decreased, while the peak attributed to 
IV.2OX became more pronounced. Finally, after 46 h the peaks at 18.5 min and 18.75 min 
were still distinguishable, suggesting that the main products were the homodimer of IV.2 and 
mixed peptide-glutathione disulfides. This was also confirmed by mass spectrometry, which 
revealed not only the presence of a product with a mass of 10270 Da corresponding to 
IV.2OX, but also the masses of glutathione adducts of both monomers. 
 
 
IV.4 Discussion 
 
Two conceivable folding models for the covalent homodimer of peptide IV.1 are shown 
in figure IV.3. In the all-parallel conformation the four helices adopt the same orientation to 
each other with the two helix-1 fragments being N-terminally linked, whereas in the other 
model the N-terminally linked helix-1 fragments are parallel to each other but anti-parallel to 
the helix-2 fragments. Thereby, the latter model resembles the one of the disulfide-bridged 
homodimer of MyoD2. In case of the IV.2 homodimer, the same models are plausible, with 
the difference that the two helix-2 fragments are C-terminally linked. The fact that the 
oxidations of both peptides IV.1 and IV.2 proceeded smoothly and almost to completeness 
suggests that the formation of the corresponding homodimers was favorable in both cases, and 
that a parallel orientation of the two helix-1 fragments in IV.1OX or the two helix-2 fragments 
in IV.2OX is possible. 
 
 
Figure IV.3. Schematic illustration of the possible folding models for the oxidized peptide IV.1. 
 
 
By contrast, the generation of the mixed dimer of IV.1 and IV.2 would propose two different 
types of helix packing, which are schematically drawn in figure IV.4. 
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Figure IV.4. Schematic illustration of the possible folding models for the mixed dimer of peptides IV.1 and 
IV.2. 
 
 
In both possible dimeric arrangements helix-1 of IV.1 and helix-2 of IV.2 would adopt an 
anti-parallel orientation to each other. As the thiol exchange assay did not show the formation 
of covalent heterodimers, it can be assumed that an interchain anti-parallel arrangement of 
helix-1 and helix-2 is unfavored. Moreover, as the homodimer IV.2OX was still present in the 
glutathione containing buffer, whereas the homodimer IV.1OX was converted into mixed 
disulfides with the glutathione, it can be suggested that the covalently linked second helices 
experience a better stabilization in comparison to the covalently linked first helices. This may 
reflect the superior intrinsic helix propensity of helix-2 with respect to helix-1, which could 
also better promote helix interaction and dimerization. 
 
 
CC
Helix-1 Helix-1’
N N 
Figure IV.5. Homodimer of the bHLH-LZ motif of Max obtained from a co-crystal with DNA.6 The C-terminal 
LZ region, the N-terminal DNA-binding region as well as the DNA strands were omitted for reasons of clarity. 
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Taken together, the results suggest that the following helix arrangements are favored in 
the Id1 HLH dimer: helix-1 parallel to helix-1’, helix-2 parallel to helix-2’, and helix-1 
parallel to helix-2’. These arrangements correspond to an all-parallel four-helix bundle, as it 
was also found in the crystal structures of the DNA-bound non-covalent homodimers of the 
related proteins MyoD7, E478 and Max6; the crystal structure of the latter is exemplarily 
shown in Figure IV.5. 
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V Solution NMR studies on the Id2 HLH motif 
 
 
V.1  Introduction 
 
 
The biological functions of the HLH proteins are strongly dependent upon equilibria 
between their monomeric and homo-oligomeric forms, which regulate their interactions with 
other HLH proteins and/or with the DNA.1, 2 Due to their pronounced aggregation propensity 
at the concentration range necessary for NMR measurements, only a few examples of NMR 
studies on HLH proteins have been reported thus far. Successful NMR experiments were for 
example carried out for the bHLH motifs of MyoD, a class II HLH protein and the ubiquitous 
E47, a class I HLH protein.3, 4 The NMR structure of MyoD proved to be difficult to obtain, 
as its bHLH motif was found to form predominantly tetramers that were not suitable for a 
reasonable NMR evaluation. Therefore, a covalently linked dimer was prepared by 
intermolecular disulfide bridge formation using the native cysteine residue at position 135 
(close to the C-terminal end of helix-1) and subsequently assigned by heteronuclear NMR 
experiments. The results suggest an anti-parallel 
four-helix bundle, in which the helix-1 of one 
monomer is roughly parallel to the helix-1 of the 
other monomer (Figure V.1). This NMR model 
contradicts the crystal structure of the DNA-bound 
MyoD dimer, in which all four helices are parallel. 
Another bHLH motif studied by NMR is the one 
from the ubiquitous E47 protein (class I HLH). 
This protein was found to be a suitable candidate 
for NMR measurements, as, contrarily to MyoD or 
the Id proteins, it does form stable dimers but no 
tetramers or higher-order oligomers. Helix-2 was 
found to be well-defined, as indicated by the 
presence of (i, i+3) and (i, i+4) NOE signals, 
whereas helix-1 turned out to be rather flexible 
under the conditions used. Except for the unordered basic region, which becomes structured 
only upon binding to the DNA, the obtained NMR results are in good agreement with the 
crystal structure of the DNA-bound E47 dimer, which shows a parallel four-helix bundle.5 
Figure V.1. Model of the Cys135 disulfide 
bonded dimer of MyoD bHLH.3
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Moreover, the whole HLH domain of the E47 protein features a high degree of dynamics, as 
indicated by the rapid hydrogen-deuterium exchange. 
The tertiary/quaternary structure of the Id proteins is thus far not known, but, based on 
sequence alignment and homology models, it is proposed to be similar to the parallel four-
helix bundle ascertained in the crystal structures of the related proteins MyoD and E47.6 The 
conformational information available for the Id proteins is, up to now, limited to the 
secondary structure elements composition obtained by the analysis of CD data.7 We 
envisioned that NMR experiments could provide a more detailed look on the structural 
preferences of the HLH motifs of the Id protein family. Like the other HLH proteins, also the 
Id proteins aggregate upon NMR conditions and present poor solubility; therefore, in order to 
avoid, or at least to reduce strong aggregation and to prevent precipitation during the NMR 
measurements, we decided to add the fluorinated alcohol trifluoroethanol (TFE) which is 
known to destroy tertiary and quaternary aggregations while, at the same time, it elicits the 
secondary structure propensity of a peptide chain. Although their use generates a non-
physiological environment, the addition of fluorinated alcohols can still yield useful insights 
in the intrinsic structural features of a peptide. Interestingly, some reports also suggest the use 
of alcohols (MeOH or EtOH) and fluorinated alcohols like TFE to mimic the physiological 
environment near membranes or in the membrane, respectively.8 Although it has to be kept in 
mind that the Id proteins are not membrane proteins, their biological functions require the 
crossing of the nuclear membrane in a receptor-independent manner and, thus, TFE 
conditions could also mirror physiologically relevant structural properties. Finally, the 
moderate length of 41 amino acids of the Id2 HLH domain benefits the acquisition of 
reasonable NMR data without isotope labeling, as it was already demonstrated for other 
peptides of similar lengths.9-12 Thus, we assembled the Id2 HLH sequence 36-76 by using 
straight-forward SPPS methodology and undertook its NMR characterization. 
 
 
V.2 Results 
 
V.2.1 CD measurements 
 
As the Id2 HLH motif is not soluble at a pH value of about 7 over the concentration 
range required for the NMR experiments (≥ 0.5 mM), we dissolved the peptide in non-
buffered water. Moreover, to further increase the solubility and to avoid precipitation, also 
TFE had to be added. To examine the influence of the pH value and the TFE addition on the 
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secondary structure of the Id2 HLH motif, CD measurements were performed before 
commencing the NMR experiments (Figure V.2). 
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Figure V.2. CD spectra of the Id2 HLH motif (30 µM). Left panel: peptide dissolved in 0.1 M phosphate buffer 
(pH 7.25) or in millipore water. Right panel: peptide dissolved in millipore water containing increasing amounts 
of TFE. 
 
 
The obtained CD curves suggest a helical conformation for all measured samples, as 
indicated by the two negative bands at 208 nm and 222 nm, respectively, and by the 
maximum at 190 nm. Nevertheless, changing the pH from a neutral to an acidic value, as well 
as adding TFE affected the peptide structure. Indeed, the intensity of the CD bands decreased 
when going from neutral to acidic conditions (Figure V.2, left panel), indicating a slight loss 
of helicity. Moreover, the ratio between the two ellipticity minima at 222 nm and 208 nm, R 
= [Θ]222/[Θ]208, also decreased, reflecting changes in the interhelical contacts upon altering 
the charge distribution of the ionizable side chains. On the other hand, the loss of ellipticity 
observed when changing from a neutral to an acidic pH value could be compensated by the 
addition of TFE (Figure V.2, right panel). This increase in CD intensity was accompanied by 
a decrease in the ratio R from 0.88 in millipore water to 0.74 in a 60% TFE containing 
mixture. However, these changes were anticipated, as TFE is known not only for stabilizing 
the secondary structure preferences of a peptide, but also for destroying interhelical 
interactions. To quantify the obtained CD data, they were subjected to CONTIN analysis. For 
the peptide in millipore water a helical percentage of 49% was calculated, corresponding to 
20 amino acids in a helical conformation. In comparison thereto, the percentage of helical 
secondary structure for the peptide in a 60% TFE solution was markedly increased: 72% helix 
content stemming from 30 helical amino acids. As the obtained CD spectrum of the peptide in 
 59
V  NMR studies on the Id2 HLH motif  
60% TFE supported the presence of a structured peptide, which is a prerequisite for a 
reasonable NMR investigation, we chose these conditions to record the NMR spectra. 
 
 
V.2.2 NMR measurements 
 
The NMR sample of the Id2 HLH peptide was prepared by dissolving it in a mixture 
of TFE-d2/water 60:40 (v/v) to a final peptide concentration of 0.5 mM. At first, 1D-NMR 
spectra were recorded at different temperatures in 6 K steps from 300 K to 318 K and 
evaluated in terms of minimal signal overlapping and maximal signal dispersion. As at 318 K 
(Figure V.3) the best results were obtained, the subsequent 2D-NMR experiments were 
performed at this temperature. 
 
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm 
Figure V.3. 1H-NMR spectrum of the Id2 HLH motif in TFE-d2/water (60:40, v/v) recorded at 318 K. 
 
 
The fingerprint region of the COSY spectrum showed a good dispersion of the 39 non-proline 
NH-αH cross signals in the region from 8.6 to 7.4 ppm, indicating the presence of a 
structured peptide. Moreover, no major spectral overlaps could be detected, which facilitated 
the sequential assignment and, indeed, the obtained resolution of the two-dimensional spectra 
proved to be sufficient enough for the assignment of the 41 amino acids (Figure V.4. See 
Appendix IX for the complete list of the chemical shifts). 
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V.2.3 Chemical shift indices (CSIs) of the αH protons 
 
The deviations of the αH chemical shifts obtained for the Id2 HLH peptide from those 
provided by Schwarzinger et al. for a random coil protein in acidic 8 M urea13 are reported in 
Figure V.5. The CSI pattern is dominated by negative values, indicating the predominance of 
a helical structure. More precisely, one large helical segment extends from residue 19 to the 
C-terminal end at position 41, whereas another one spans from the N-terminal end to residue 
14 but is interrupted by two positive CSI values at positions 8 and 9. As clearly opposite CSI 
values of two adjacent residues are indicative for a transition from one secondary structure 
element to another14, it is likely that this short inversion of the CSI values reflects the 
presence of a turn or bent connecting two short helical elements (4-7 and 10-14). Furthermore, 
the central region 15-18 shows nearly neutral or positive CSI values and might correspond to 
the loop region predicted by sequence alignment. 
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Figure V.5. CSIs for the αH protons of the Id2 HLH motif in TFE-d2/water (60:40) at 318 K. The calculation 
was done using the reference values reported by Schwarzinger et al.13 
 
 
V.2.4 NOE signals 
 
The NOESY spectrum (recorded with a mixing time of 200 ms) was examined for NOE 
signals that are characteristic for the presence of secondary structure elements (Figure V.6). 
Unfortunately, the presence of some relevant NOE signals could not be evaluated, due to 
considerable overlap. Nevertheless, several medium to strong dNN(i,i+1), dαβ(i,i+3) and 
dαN(i,i+4) NOE signals were found in the C-terminal part of the sequence spanning the 
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residues 29-40, indicating the presence of a well-defined α-helix in this region. Such NOE 
pattern agrees with the CSI values found for the same residues, which were remarkably more 
negative than those of the preceding residues 19-28, suggesting that this C-terminal helix is 
better defined at its C-terminus, while its N-terminal tail being probably more flexible. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
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dαN(i,i+3)
dNN(i,i+1)
 
Figure V.6. NOE cross signals obtained for the Id2 HLH motif. Missing bars indicate the absence of NOE 
signals. Open bars indicate the presence of overlapping that made it impossible to verify the presence of a NOE 
signal. 
 
 
Contrarily to the C-terminal part of the sequence, the N-terminal part showed only few 
dNN(i,i+1) and no dαβ(i,i+3) NOE signals. However, two dαN(i,i+2) NOEs were present 
between residues 4-6 and 7-9, which might reflect the formation of turns or of a short 310-
helix. 
 
 
V.3 Discussion 
 
The presented results provide the first NMR spectroscopic evaluation of the Id2 HLH 
motif. Despite its tendency to aggregate, the use of a non-buffered solution and the addition 
of TFE enabled the acquisition of reasonable NMR spectra. The spectral dispersion of the 
signals was sufficient enough to allow the sequential assignment and, subsequently, a first 
conformational analysis of this peptide. The CD study already anticipated the high helix 
content, which can be partly attributed to the addition of TFE. This result was confirmed by 
the analysis of the CSI values which suggest that the peptide is presumably adopting an α-
helical structure starting from Pro19, as supported also by the presence of several sequential 
and medium-range NOEs. The identified α-helix spanning from Pro19 to Gln41 is apparently 
longer than the one predicted by sequence alignment studies which locate the start of the 
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helix-2 at Lys26. This might be explained by the strong influence of TFE on the stabilization 
of the secondary structure. However, it should be pointed out that the N-terminal tail of the 
helix-2 was not as rich in NOE connectivities as the C-terminal part. The loop region N-
terminal to the helix-2 seems to be restricted to the residues 14-18, which would result to be 
much shorter than the predicted nine residues 17-25. In contrast to the remarkable helical 
character of the second half of the peptide, the predicted N-terminal helix-1 from residue 1 to 
residue 16 was poorly defined, as indicated by a scarce number of sequential and medium-
range NOE signals. In particular, the lack of NOEs characteristic for α-helices might be 
explained by non-classical helix elements of a highly dynamic conformation, as it was 
already observed for the helix-1 of the E47 HLH domain4 and for the HLH domain of Max, a 
class IV protein15. In these studies the reduced number of sequential and medium-range 
NOEs was attributed to a poorly defined first helical region. Moreover, the NMR data 
presented here are consistent with our previous reports upon the superior helix propensity of 
the second helix of the Id HLH motif compared to the N-terminal region, as investigated by 
CD spectroscopy.16 However, the majority of negative CSI values as well as the presence of 
some dαN(i,i+2) NOEs suggest the tendency to form local helical turns or a nascent helix, 
whose conversion into a stably folded α-helix might correlate with the possibility to interact 
with the helix-2. The conditions used in the presented NMR study are not favorable to and 
rather prevent interhelical contacts, as TFE is known for destroying tertiary and quaternary 
folds.17 Thus, it is reasonable that the peptide in the presence of a high content of TFE is not 
able to adopt a compact structure, but rather an opened conformation that might be also 
dictated by the N-terminal prolongation of the helix-2 at the expense of the central loop 
region. Finally, it can be suggested that the structural flexibility of the first helix constitutes a 
prevailing structural feature occurring in the whole HLH protein family, and is likely to 
provide the binding specificity to other proteins.  
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VI  Toward the recognition of the Id HLH motif by an artificial 
receptor 
 
 
VI.1 Introduction 
 
Protein-protein interactions play a key role in many biological processes, including 
signal transduction, cell-cell contacts, immunitary response and DNA transcription. As they 
are involved both in normal and pathologic events, a major interest lies not only in a better 
understanding of underlying mechanisms of protein molecular recognition, but also in the 
development of new chemical tools to influence such mechanisms, especially in cancer 
pathways.1-4 A range of artificial systems functioning as dimerizers, inhibitors of dimerization 
or inhibitors of protein-receptor interactions have successfully been developed.5 The 
challenge of targeting protein interfaces arises from their large area (usually >600 Å2) and the 
highly specific distribution of a variety of functional groups (charged, polar, hydrophobic, H-
bond acceptors/donors) on it. Nonetheless, recent approaches based on the design of protein-
surface mimetics or protein-surface artificial receptors have been proven to be promising for 
the detection and/or inhibition of protein-protein activities. One of these approaches consists 
of the application of molecules incorporating transition metal ions with high affinity for 
specific amino acid side chains. For example, Mallik and co-workers have synthesized an 
artificial receptor bearing three CuII-IDA (iminodiacetic acid) units for the recognition and 
binding of three histidine side chains located at the N-terminus of the protein carbonic 
anhydrase.6 Another interesting approach is to combine different functionalities into one 
receptor molecule to increase its multiplicity of interactions, including hydrophobic and 
electrostatic contacts. Such multivalent receptors have been used to selectively target peptide 
sequences in aqueous solutions: for example, Hossain and Schneider developed an artificial 
receptor containing an 18-crown-6 ether, a peralkylammonium group and a dansyl group for 
the sequence-selective binding of zwitterionic tripeptides bearing a central aromatic residue 
like phenylalanine or tryptophan.7 
Recently, König and co-workers reported on the ditopic receptor R1 featuring a CuII-
IDA complex for the binding of a Lewis-base and a crown ether for binding to a Lewis-acid 
(Figure VI.1).8 A phthalic diester unit incorporated in the crown ether allows the monitoring 
of cation coordination by measuring the increase in emission intensity at 394 nm. However, a 
fluorescence response is only observed when the ligand is able to simultaneously bind to the 
CuII-IDA, as the crown ether interaction for itself is generally too weak. Among several tested 
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di- and tripeptides, only those containing an N-terminal histidine residue adjacent to a lysine 
or a glycine were found to bind the receptor. The highest affinity was observed for the 
dipeptide H-His-Lys-OMe. 
 
 
 
R1 
R2 
 
Figure VI.1. Structures of the receptors R1 and R2 developed by König and co-workers.8 
 
 
The IDA unit, complexed with copper or nickel, has found wide application in 
immobilized metal affinity chromatography (IMAC), a technique which is used for enriching 
or purifying proteins. The proteins are separated on the basis of the density of electron donors 
on their surface, like the side chains of cysteine, histidine or tryptophan, which stick to the 
immobilized Lewis acidic copper complex. At neutral pH the affinity of amino acids towards 
the metal complex is as follows: Cys > His >> Asp, Glu > Trp, Tyr, Lys, Met, Asn, Gln, Arg.9 
Furthermore, Nomura et al. proved the application of CuII-IDA as paramagnetic probe for the 
elucidation of long distance information: by NMR experiments they showed the localization 
of the CuII-IDA to a histidine residue on the surface of ubiquitin.10 
Another receptor molecule developed by König and co-workers presents a CuII-NTA 
(nitrilotriacetic acid) unit in place of the CuII-IDA (R2, Figure VI.1). The CuII-NTA complex 
is also frequently used in IMAC and exhibits a higher metal binding affinity at the expense of 
the protein binding, which is lower due to the loss of one coordination site.11 
The aim of the presented work was to apply the receptor R1 for recognition and non-
covalent fluorescence labeling of the native dimerization domain of the Id proteins. Also the 
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more recently developed receptor R2 was tested to elucidate the influence of the metal 
complex on the binding properties.  
 
 
VI.2 Results 
 
To investigate potential interactions of the receptor R1 with the Id HLH regions, four 
41-residue long peptides based on the HLH sequences of Id1-4 were synthesized by solid-
phase methodology (Table VI.1).  
 
Table VI.1. Synthesized peptides tested for receptor affinity. All peptides were N-terminally acetylated and C-
terminally amidated. 
 
No. Description Helix-1 Loop Helix-2 
III.1 (66-106)-Id1 LYDMNGCYSRLKELVP TLPQNRKVS KVEILQHVIDYIRDLQ 
VI.1 (36-76)-Id2 LYNMNDCYSKLKELVP SIPQNKKVS KMEILQHVIDYILDLQ 
VI.2 (41-81)-Id3 LDDMNHCYSRLRELVP GVPRGTQLS QVEILQRVIDYILDLQ 
VI.3 (65-105)-Id4 QCDMNDCYSRLRRLVP TIPPNKKVS KVEILQHVIDYILDLQ 
VI.4 (66-82)-Id1 LYDMNGCYSRLKELVP T  
VI.5 (41-57)-Id3 LDDMNHCYSRLRELVP G  
VI.6 (65-81)-Id4 QCDMNDCYSRLRRLVP T  
VI.7 (90-105)-Id4   KVEILQHVIDYILDLQ 
VI.8 (72-75)-Id1       CYSR   
VI.9 [A73]-(72-75)-Id1       CASR   
VI.10 [A72]-(72-75)-Id1       AYSR   
VI.11 (42-45)-Id2       CYSK   
VI.12 (47-52)-Id3       CYSRLR   
VI.13 (122-160)-MyoD LSKVNEAFETLKRCTS SNPNQRLP KVEILRNAIRYIEGL 
VI.14 (36-74)-Max RDHIKDSFHSLRDSVP SLQGEKAS RAQILDKATEYIQYM 
 
 
Formation of the receptor-peptide complex in a HEPES buffered solution (50 mM, pH 
7.5) at 25 °C was monitored by fluorescence spectroscopy, following the change of the 
receptor emission intensity at 394 nm (λex = 305 nm) upon addition of the peptides. As they 
feature several groups which are prone to interact with the copper complex (imidazole, thiol, 
carboxylic groups and, to a minor extent, backbone amides) and with the crown ether 
(arginine and lysine side chains), the Id HLH motifs could be potential ligands of R1. Indeed, 
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an interaction between the receptor and the Id sequences was detected. In order to identify the 
region responsible for the binding, also the single helices and parts of them were synthesized 
and tested for receptor affinity. The results of these experiments are described in the 
following.  
 
 
The Id HLH domains 
 
The fluorescence intensity of a solution of R1 was monitored upon titration with each of 
the four peptides reproducing the 41-residue long HLH sequences of Id1-4 (peptides III.1 and 
VI.1-VI.3; Figure VI.2 and Table VI.1).  
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Figure VI.2. Titration curves of R1 (9.5 µM in 50 mM HEPES buffer, pH 7.5) with peptides III.1 (A), VI.1 (B), 
VI.2 (C) and VI.3 (D). Solid lines represent the data fit obtained using the Hill equation. Indents: Job’s plot 
analyses. 
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Upon increasing peptide concentration, the emission intensity of R1 also increased, thus 
indicating cation coordination to the crown ether and, consequently, an interaction between 
R1 and the peptide. In case of peptides III.1 and VI.1, the fluorescence signal reached its 
maximum at ~0.5 equiv. peptide, suggesting a 2:1 R1/peptide ratio. Further increase in 
peptide concentration led to a decrease in fluorescence, which was accompanied by the 
appearance of a white precipitate (see Appendix, Figure IX.5). As the peptides themselves are 
completely soluble in the concentration range used, the turbidity might be attributed to a 
change in the solubility properties of the peptides in the titration mixture, presumably as a 
consequence of a conformational transition which elicited their self-association. 
Similar titration curves were obtained for peptides VI.2 and VI.3, for which, though, the 
fluorescence maximum was shifted to ~0.8 equiv. peptide, and the decrease in fluorescence 
intensity above this value was less pronounced, especially in case of VI.2. Moreover, no 
turbidity was observed during the titration of these two HLH motifs. To examine the binding 
stoichiometries, Job’s plot analyses were conducted. For peptides III.1, VI.1 and VI.2 an 
ambiguous stoichiometry of ~1.6:1 (R1/peptide) was obtained, whereas peptide VI.3 showed 
a 1:1 stoichiometry. As the shape of the curves was quite broad for all four peptides, the 
coexistence of different complex species in equilibrium can be assumed. By fitting the data 
preceding the fluorescence decrease with the Hill equation, K0.5 values in the range of 1.5-2.5 
µM were determined, with a Hill coefficient h increasing from 1.5 for III.1 to 1.9 for VI.3. 
 
Isolated Id helices 
 
To investigate the role of each single helix in the interaction with R1, we prepared 
peptides VI.4-VI.7 (Table VI.1), reproducing the N-terminal helix (helix-1) of Id1 (VI.4), Id3 
(VI.5) and Id4 (VI.6), and the C-terminal helix (helix-2) of Id4 (VI.7). All these peptides but 
VI.7 showed a fluorescence response comparable to the one obtained for the full-length HLH 
motifs (Figure VI.3), indicating that helix-1 contains the site responsible for receptor binding. 
Peptide VI.6, representing the first helix of the Id4 HLH motif, exhibits the smallest K0.5 
value among the isolated helices with 1.4 µM. The corresponding helices of Id1 and Id3 
(peptides VI.4 and VI.5) show a moderately reduced binding with K0.5 values of 3.2 µM and 
2.1 µM, respectively. The putative binding motif of the helix-1 of the Id HLH domains might 
correspond to the conserved tetrapeptide CYSR(K), which is characterized by the presence of 
a cysteine residue at position i and of a basic residue (lysine for Id2 and arginine for the other 
Id proteins) at position i + 3. The moderately different K0.5 values shown by the three helix-1 
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segments probably reflects the less conserved amino acid positions in the first half of the 
sequences: indeed, the first two residues in peptide VI.6 are glutamine and cysteine, which are 
found only in Id4, whereas peptides VI.4 and VI.5 start with leucine-tyrosine and leucine-
aspartic acid, respectively. Moreover, the CYSR(K) motif is preceded by aspartic acid in 
peptide VI.6, by glycine in peptide VI.4 and by histidine in peptide VI.5. These changes are 
likely to influence the binding and seem to have the most positive impact on peptide VI.6. 
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Figure VI.3. Titration curves of R1 (9.5 µM in 50 mM HEPES buffer, pH 7.5) with peptides VI.4 (A), VI.5 (B), 
VI.6 (C) and VI.7 (D). Solid lines represent the data fit obtained using the Hill equation. Indents in panels A, B 
and C: Job’s plot analyses.  
 
 
In contrast to the Id helix-1 sequence, the helix-2 (only the Id4 helix-2, peptide VI.7, 
was used for this study, as all second helices of the Id family are highly identical) shows low 
affinity to the receptor. Although the CYSR(K) sequence is not present, other residues 
potentially binding to the receptor can be found, including lysine and histidine at positions i 
and i + 6, respectively. One reason for the weak fluorescence response might be an 
inappropriate side-chain distribution along the sequence, which does not allow simultaneous 
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interactions of the peptide with the two receptor binding sites. Furthermore, it must be noted 
that the Id helix-2 shows a high intrinsic propensity to fold into stable amphiphilic α-helices 
which can undergo self-association. This results in a well-defined side-chain arrangement on 
the helical surface, in which most of the potential CuII-IDA interacting residues, including 
histidine, aspartic and glutamic acid, and glutamine, would be located on the opposite helical 
face with respect to lysine. By contrast, the Id helix-1 possesses a very low intrinsic helix 
propensity and is, therefore, assumed to be rather flexible as isolated fragment. Moreover, the 
putative receptor binding site CYSR(K) features a cysteine residue, which is a strong CuII-IDA 
binder, and, two residues farther, a guanidinium or ammonium ion, which are potential 
ligands for the crown ether. 
 
 
The CYSR(K) motif 
 
To collect further evidence for the proposed receptor binding motif within the helix-1, 
we used a minimalist approach and examined the binding properties of several small peptides 
containing the CYSR(K) sequence (peptides VI.8 and VI.11), and variations thereof: CASR 
(VI.9), AYSR (VI.10) and CYSRLR (VI.12). Peptides VI.8, VI.11 and VI.12, featuring the 
native sequences, bind to R1 with K0.5 values of 3.2 µM, 2.9 µM and 4.3 µM, respectively, 
and with a receptor/peptide stoichiometry of 2:1, as extrapolated by the Job’s plots (Figure 
VI.4). These K0.5 values suggest that the CYSR(K) motif is sufficient to bind the receptor in 
the low-micromolar range. Interestingly, the isolated CYSR motif showed an affinity 
comparable to the complete Id1 helix-1 (peptide VI.4), which points to a negligible 
contribution of the flanking amino acids in the longer peptide to the stabilization of the 
receptor/ligand complex. By contrast, the neighboring residues present in the Id3 and, 
especially, Id4 helix-1 (peptides VI.5 and VI.6) seem to positively affect the binding, 
resulting in lower K0.5 values (2.1 µM and 1.4 µM, respectively). Strikingly, C-terminal 
elongation of the CYSR motif with leucine and an additional arginine (peptide VI.12) slightly 
impairs the binding. This might be caused by a competition between the two arginine residues 
for the coordination to the crown ether. 
Substitution of the tyrosine residue adjacent to cysteine with an alanine (peptide VI.9) is 
accompanied by a slight increase in the K0.5 value (from 3.2 µM for VI.8 to 3.5 µM for VI.9), 
leading to the assumption that the phenol ring positively influences the binding. Finally, the 
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replacement of cysteine with alanine (peptide VI.10) leads to a dramatic loss of fluorescence 
response, indicating the need for a thiol group to obtain a strong binding to R1. 
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Figure VI.4. Titration curves of R1 (9.5 µM in 50 mM HEPES buffer, pH 7.5) with peptides VI.8 (A), VI.9 (B), 
VI.10 (C), VI.11 (D) and VI.12 (E). Solid lines represent the data fit obtained using the Hill equation. Indents in 
panels A and B: Job’s plot analyses.  
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HLH domains of related proteins 
 
As within the HLH protein family the CxxR/K motif is only found in the helix-1 of the 
Id proteins, we reckoned that the receptor R1 might show some selectivity towards this 
subgroup of the HLH superfamily. Therefore, we tested the HLH motifs of MyoD (VI.13) and 
Max (VI.14), which are both natural dimerization partners of the Id proteins. Like the Id HLH 
motifs, also the MyoD HLH motif contains a cysteine residue preceded by two adjacent basic 
residues (KRC) in proximity of the C-end of helix-1. Nevertheless, peptide VI.13 shows a 
reduced binding affinity to R1 compared to the Id HLH motifs (Figure VI.5). A similar 
binding behavior is observed for the Max peptide VI.14, despite the presence of two histidine 
residues in the first helix at positions 3 and 9 close to basic residues like Lys5 and Arg12. 
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Figure VI.5. Titration curves of R1 (9.5 µM in 50 mM HEPES buffer, pH 7.5) with peptides VI.13 (A) and 
VI.14 (B). Solid lines represent the data fit obtained using the Hill equation. 
 
 
Summary 
 
For all measured peptides the K0.5 and h values were obtained from the Hill fitting of the 
curves (Table VI.2). The K0.5 values for the Id sequences increased in the order: Id2 HLH 
motif, Id4 helix-1 (~ 1.5 µM) < Id1 HLH motif, Id3 helix-1 (~ 2 µM) < Id3 HLH motif (2.31 
µM) < Id4 HLH motif (2.45 µM) < CYSR(K), Id1 helix-1 (~ 3 µM) < CASR (3.46 µM) < 
CYSRLR (4.33 µM). Higher K0.5 values (5.2-6.0 µM) were found for the peptides VI.13 and 
VI.14 representing the HLH domains of MyoD and Max. For peptides VI.7 and VI.10, 
corresponding to the Id helix-2 and to the cysteine-free tetrapeptide AYSR, respectively, no 
Hill fitting was carried out, as only a weak fluorescence response was obtained. 
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Table VI.2. Binding data for the synthetic peptides towards the receptor R1. K0.5 and h were obtained by fitting 
the experimental curves with the Hill equation. 
 
Peptide K0.5 (µM) h 
III.1 2.03 ± 0.23 1.48 ± 0.12 
VI.1 1.52 ± 0.13 1.62 ± 0.13 
VI.2 2.31 ± 0.17 1.52 ± 0.12 
VI.3 2.45 ± 0.05 1.89 ± 0.05 
VI.4 3.22 ± 0.07 1.93 ± 0.09 
VI.5 2.06 ± 0.05 1.91 ± 0.09 
VI.6 1.43 ± 0.05 2.36 ± 0.16 
VI.7 weak fluorescence response observed 
VI.8 3.15 ± 0.07 2.03 ± 0.09 
VI.9 3.46 ± 0.06 2.91 ± 0.14 
VI.10 weak fluorescence response observed 
VI.11 2.93 ± 0.06 2.33 ± 0.12 
VI.12 4.33 ± 0.09 2.42 ± 0.12 
VI.13 5.98 ± 0.20 1.65 ± 0.06 
VI.14 5.18 ± 0.15 1.92 ± 0.10 
 
 
The NTA-containing receptor 
 
To examine the influence of the metal complex on the binding, the two peptides VI.6 
and VI.8, which showed a good to moderate binding to receptor R1, and peptide VI.10, 
showing a weak fluorescence response of R1, were tested for affinity to receptor R2 that 
contains, besides a modified linker bearing an amide bond, the CuII-NTA moiety in place of 
the CuII-IDA one (Figure VI.6). In the case of the cysteine-free tetrapeptide VI.10 (AYSR), 
also the receptor R2, like R1, showed very low increase in the emission intensity upon 
increasing peptide concentration. This result was expected, as VI.10 does not contain any 
residues which are able to strongly bind to the CuII-NTA complex. Instead, increasing 
concentrations of peptides VI.6 and VI.8 were accompanied by a linear increase in 
fluorescence, which might be explained by an unspecific peptide binding to the receptor. One 
reason for the different behavior of the two receptors might be the reduced coordination sites 
at the CuII-NTA complex, which prevent a successful binding to the peptide. However, also 
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the linker of receptor R2 differs from the one of R1. While featuring the same chain length as 
the linker of R1, the linker of R2 is rigidified by the presence of a central amide bond. Thus, 
it can not be excluded that the different binding behavior towards the same peptide ligands 
might also stem from different structural properties of the receptor itself. 
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Figure VI.6. Titration curves of R2 (9.5 µM in 50 mM HEPES buffer, pH 7.5) with peptides VI.6 (A), VI.8 (B) 
and VI.10 (C). 
 
 
CD experiments 
 
As the interaction of an artificial receptor with a peptide ligand might result in a 
conformational change of the latter, we carried out CD measurements of the tetrapeptide VI.8 
in the absence and presence of different amounts of receptor R1, and analyzed the far-UV 
region that is commonly used to monitor changes in the backbone conformation (Figure VI.7). 
The tetrapeptide is flexible in water, as shown by the weak negative ellipticity between 215 
nm and 240 nm, and the strong negative band below 200 nm. With increasing concentrations 
of R1 the negative contribution to the CD curve above 215 nm diminishes and two new 
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positive bands appear at 230 nm and 245 nm. This region is usually regarded to be sensitive to 
an interaction between the electronic transition of the peptide bond and the transition of an 
aromatic amino acid.12 Thus, it can be speculated that a structural change in the peptide is 
induced upon binding to the receptor that alters the orientation of the tyrosine side chain to the 
main chain. 
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Figure VI.7.  CD spectra of R1/VI.8 mixtures in water. The concentration of VI.8 was kept constant at 305 µM, 
while the receptor concentration was varied to get receptor molar fractions xrec between 0 and 0.7. 
 
 
Like the Job’s plots, also this CD experiment seems to indicate a receptor/peptide ratio higher 
than 1, as the maximum change in the CD spectra is observed at a receptor molar fraction 
higher than 0.5. 
In addition, we also analyzed the Id4 helix-2 (peptide VI.6) in HEPES buffer (50 mM, 
pH 7.5) in the absence and presence of the receptor R1 by CD spectroscopy (Figure VI.8). 
Unfortunately, technical reasons prevented the acquisition of the CD spectra below 210 nm. 
However, above this region some conformational changes could be noticed upon receptor 
addition: for example, the negative shoulder at 220 nm of the peptide alone disappeared and 
two new ones emerged at 230 nm and 245 nm, which might reflect an elicited contribution of 
the aromatic residue to the CD spectrum. Moreover, the decrease in the negative CD 
contribution below 215 nm and the concomitant appearance of a minimum around 216-218 
nm suggest that the aperiodic, irregular peptide structure no longer prevails. 
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Figure VI.8. CD spectra of R1/VI.6 mixtures in HEPES buffer (50 mM, pH 7.5).  
 
 
Interestingly, the changes in the dichroic properties of the two peptides in the presence of the 
copper-containing receptor show some similarities to those observed for other flexible Cu2+-
binding peptides upon metal addition: in particular, the CD spectra of the tyrosine-containing 
amyloid β peptides (1-16)-Aβ and (1-28)-Aβ in water at pH 7.5-7.8 were characteristic of 
disordered structures in the absence of the metal, but displayed a positive band close to 225 
nm and a decrease in the negative band below 215 nm in the presence of the metal.13 
 
 
VI.3 Discussion 
 
The artificial receptor R1 developed by König and co-workers for the combined 
recognition of Lewis-acidic and Lewis-basic amino acid residues was shown to bind to the 
HLH domain of the biologically relevant Id proteins. By using a minimalist approach, the 
binding motif was identified to be CxxR/K, a sequence located in the N-terminal helix of the 
Id HLH motif and unique for the Id family. Therein, the accommodation of the receptor might 
be facilitated by the rather flexible conformation observed in this region. Accordingly, the 
isolated C-terminal Id helix-2 showed weak interaction with the receptor, which might not 
only mirror the lack of a strong CuII-IDA binder in proximity of a basic residue, but also the 
tendency of the helix-2 to adopt a stable helical conformation with a well-defined spatial 
distribution of the side chains. 
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Although the Id1 helix-1 is sufficient to bind the receptor in the low-micromolar 
concentration range, the increase in the K0.5 value compared to the full-length HLH motif 
suggests that additional structural and functional elements arising from the loop and/or helix-2 
can benefit the receptor binding. Contrary thereto, both the first helices of Id3 and Id4 exhibit 
smaller K0.5 values compared to those of the corresponding full-length HLH motifs, rather 
proposing a negative structural influence of the additional regions. Compared to the other 
parent Id proteins, both the helix-1 and the HLH sequence of Id4 showed another deviating 
feature: for example, the Id4 HLH motif was the only one showing a 1:1 receptor/peptide 
ratio. Presumably, the second cysteine residue in the helix-1, exclusively present in Id4, 
compensates the absence of the loop and helix-2 regions and even increases the ability of the 
isolated Id4 helix-1 to interact with the receptor, whereas this benefit might be less significant 
in the full-length Id4 HLH motif due to a more rigid helix folding. 
With the exception of the Id4 HLH peptide, all other Id peptides were characterized by a 
receptor/peptide ratio higher than one. Also for the short tetrapeptide CYSR this 
stoichiometry was observed by Job’s plot analysis and supported by CD measurements. The 
2:1 stoichiometry might result from two binding processes: a first receptor molecule 
specifically binds to the epitope CxxR/K, while a second one non-specifically binds to the 
peptide backbone (Scheme VI.1). In fact, the ability of backbone amides to coordinate Cu2+ 
has been described for some peptide sequences, primarily for the amyloid peptide Aβ.14, 15 
 
Scheme VI.1. A possible 2:1 binding model for the R1/CxxR complex. Peptide in blue, receptor molecules in 
black. Vacant coordination sites may be occupied by water. 
 
 
 
Also for the peptides that do not contain the CxxR/K motif, an increase in peptide 
concentration was accompanied by a slight, but nevertheless detectable increment of the 
fluorescence response, which might stem from a receptor molecule anchored to the peptide 
backbone by its CuII-IDA complex. 
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The identified CxxR/K sequence might represent a target for the selective recognition of 
the Id proteins, as it is not found in the related HLH proteins.16 The selectivity of the receptor 
towards this binding motif was tested with measurements on the HLH motifs of the Max and 
MyoD proteins, which, indeed, showed a moderately reduced binding compared to the Id 
HLH domains (Figure VI.9). Obviously, clearly superior affinity and selectivity are needed 
for an artificial receptor to be applied as a tool for the Id protein targeting. However, this 
study is the first attempt of molecular recognition of the dimerization domains of the Id 
proteins and may represent a starting point for the development of chemical devices able to 
modulate the protein-protein interactions involving the Id family. 
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Figure VI.9. Superposition of the titration curves of receptor R1 with the HLH motifs of Id2 (VI.1), MyoD 
(VI.13) and Max (VI.14). 
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VII Summary 
 
The Id proteins take part in many fundamental physiological processes during 
development and tumor-related events. A characteristic of these rather small proteins (119 up 
to 161 amino acids long) is a highly conserved dimerization domain, the helix-loop-helix 
(HLH) motif, which allows them to homo- or heterodimerize and makes them a subfamily of 
the large HLH protein family. Their preferred binding partners are transcription factors from 
the same family, whose homo- or heterodimers are able to bind to DNA by basic residues 
adjacent to the N-terminal end of the HLH fold. As the Id proteins lack such a basic region, 
dimers formed under their participation lose their ability to bind to DNA and, thus, 
transcriptional activation is blocked. By using this mechanism of inhibition of DNA binding, 
the Id family members regulate cellular processes like proliferation and differentiation. 
Although recent works also reported on non-HLH proteins able to interact with the Id proteins, 
dimerization with related HLH proteins seems to remain the major mode of action of the Id 
proteins. Structural information on the Id proteins is scarce and was so far deduced by 
sequence alignment and homology studies based on known HLH structures, disregarding their 
unique position within the HLH protein family. 
The goal of the presented work was the elucidation of the conformational features 
underlying the Id HLH fold. For this purpose, the native Id sequences as well as a series of 
analogs based on amino acid substitution/truncation/deletion, sequence inversion (retro 
sequence) and disulfide bond formation were synthesized by solid-phase methodology and 
characterized by CD and NMR spectroscopy. In addition, the ability of small molecule 
receptors to bind to the Id HLH motifs was investigated by fluorescence spectroscopy. 
A first approach was based on the design of Id1 HLH analogs displaying modified loop 
regions and/or the retro sequence of the first helix. As shown by CD experiments, the 
synthesized peptides possessed a broad diversity in terms of secondary structure elements 
composition. An analog containing the HLH domain with the retro helix-1 showed superior 
propensity to aggregate compared to the native HLH motif, as indicated by poor solubility in 
aqueous solutions. Nevertheless, this analog turned out to have an increased helical content, 
proving the importance not only of the interhelical side-chain packing, but also of the helix 
dipole arrangement for the HLH fold stabilization. The shortest analog that maintained a 
comparable helicity to the full length HLH motif was the one containing a δ-ornithine residue 
in place of the native loop region, which should restrict the backbone conformational freedom 
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to an anti-parallel orientation of the helix dipoles, and the retro sequence of the first helix, 
which should allow for parallel side-chain orientation. 
Further, by using tyrosine/phenylalanine replacement Id1 HLH analogs were obtained 
which showed a superior helicity compared to the native sequence, thus underlining the fact 
that the natural tyrosine side chains are predominantly participating in hydrophobic 
interactions, which result in the formation and stabilization of the hydrophobic core of the 
protein fold. Also the presence of cation-π interactions could explain the positive effect of the 
tyrosine/phenylalanine substitution, as phenylalanine stabilizes such contacts better than 
tyrosine. 
In another approach, covalently linked Id1 HLH dimers were formed by cysteine 
oxidation of analogs that contained GGC units attached to either the N-terminal or the C-
terminal ends of the HLH motif, respectively. The oxidation proceeded fast and almost to 
completion, as monitored by mass spectrometry and analytical HPLC, indicating that a 
parallel orientation of the first and second helices, respectively, should be favored in the HLH 
dimer. A thiol exchange assay did not produce the heterodimer, in which the helix-1 and the 
helix-2 of the corresponding monomer would adopt an anti-parallel conformation. This 
observation supports a preferred parallel orientation of the helices in the Id1 HLH dimer, as it 
was also shown in the crystal structures of E47 and MyoD. 
To further characterize the structural properties of the Id HLH fold, the HLH domain of 
the Id2 protein was investigated by NMR spectroscopy. Due to its pronounced aggregation 
tendency, the fluorinated alcohol TFE had to be added to improve the peptide solubility to a 
level, at which reasonable NMR spectra could be recorded. Indeed, the quality of the obtained 
NMR spectra proved to be sufficient to achieve the sequential assignment of the peptide. The 
chemical shift index (CSI) and the NOE patterns suggest the presence of a poorly defined N-
terminal helix and of a stable C-terminal α-helix, connected by a short flexible region. These 
results are in accordance with NMR spectroscopic investigations on the related HLH domains 
of E47 and Max. 
Finally, the ability of a ditopic receptor to bind to the Id HLH motifs was investigated 
by fluorescence spectroscopy. The receptor consists of a fluorescent crown ether unit linked 
to a CuII-IDA complex by an alkyl chain. Only upon simultaneous binding to both moieties a 
fluorescence response is triggered. The receptor was shown to bind to peptides representing 
the four Id HLH domains with K0.5 values ranging from 1.5 µM to 2.5 µM. Further binding 
experiments on shorter Id peptide fragments allowed the identification of the tetrapeptide 
CxxR/K as strong binding motif located in the first helix of the Id HLH domains. The receptor 
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showed also moderate selectivity towards the Id HLH motifs compared to the ones of the 
related HLH proteins MyoD and Max, which showed K0.5 values of 6.0 µM and 5.2 µM, 
respectively. A similar receptor, containing a CuII-NTA in place of the CuII-IDA unit and a 
modified linker between the crown ether and the metal complex, did not succeed to bind the 
CxxR motif. 
In conclusion, the presented work has provided additional information on the structural 
properties of the Id proteins. The oxidized Id1 HLH dimer is likely to prefer a parallel helix 
arrangement. Previous reports on the increased flexibility of helix-1 compared to helix-2 
could be supported by the NMR data obtained for the Id2 HLH domain. By using a 
fluorescent artificial receptor, a unique tetrapeptide motif within the helix-1 could be 
identified, which might represent a starting point for the development of Id specific markers 
and small molecules able to interfere with the Id cellular pathways. 
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VIII Experimental part 
 
VIII.1 Materials 
 
The Nα-Fmoc protected amino acids and HBTU were purchased from MultiSynTech 
(Witten, Germany); Fmoc-ε-aminohexanoic acid, Fmoc-β-alanine, Fmoc-ornithine(Mtt) and 
Fmoc-lysine(Mtt) were obtained from Novabiochem (Darmstadt, Germany). Peptide-
synthesis grade DMF, NMP, piperidine and diethylether, ACN and TFA for spectroscopy 
were purchased from Biosolve (Valkenswaard, The Netherlands). HOBt, DIEA, TFA, DCM, 
DMSO, HEPES, reduced L-glutathione, oxidized L-glutathione and α-cyano-4-hydroxy-
cinnamic acid for mass spectrometry were bought from Fluka (Taufkirchen, Germany). 
Methanol was obtained from J.T. Baker (Deventer, The Netherlands), TIS from Aldrich 
(Steinheim, Germany) and TFE from Acros (Geel, Belgium). EDT, acetic anhydride, acetic 
acid, NaH2PO4 and Na2HPO4 were purchased from Merck (Darmstadt, Germany). TFE-d2 and 
D2O were from Deutero (Kastellaun, Germany). 
 
 
VIII.2 Methods 
 
VIII.2.1 Peptide synthesis and purification 
 
VIII.2.1.1 Solid-phase peptide synthesis (SPPS) 
 
Developed in 1963 by the late Bruce Merrifield (Nobel Prize 1984) and steadily being 
improved since then, the solid-phase methodology is an indispensable tool for the synthesis of 
peptides and proteins, whose preparation by biochemical methods is challenging or 
impossible.1 The C-terminal amino acid of the peptide to be synthesized is attached to an 
insoluble solid support via a so-called linker and, step by step, elongated with the successive 
amino acids (Scheme VIII.1). As excess reagents are washed away, tedious purification steps 
after each reaction, as in solution chemistry, are avoided. Moreover, this strategy is suitable 
for an automated process, which led to the development of sophisticated peptide synthesizers. 
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Scheme VIII.1. Fmoc-strategy based solid-phase peptide synthesis. PS: polymer matrix copoly(styrene-1% 
DVB); AA: amino acid. 
 
 
 
Solid support and linker 
The polystyrene beads used as solid support are functionalized with a linker, which 
serves as point of attachment for the first amino acid. The different commercially available 
resins distinguish themselves by the type of linker, which allows the preparation of peptides 
with different C-terminal ends, including acids, amides, hydrazines and aldehydes. The 
peptides presented in this work were synthesized on Rink amide MBHA resin (Scheme VIII.2) 
to obtain them as peptide amides. 
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Scheme VIII.2. Rink amide MBHA resin. 
 
 
 
 
Amino acid coupling 
The reaction between an amine and a carboxylic acid to obtain a peptide bond requires 
the use of activation reagents. Widespread used in SPPS are phosphonium (PyBOP) or 
uronium salts (HBTU, TBTU, HATU) which all allow an in situ active ester formation. 
 
Protecting groups 
The synthesis of peptides necessitates the use of appropriate protecting groups. While 
the side-chain functionalities have to be protected permanently during the synthesis to prevent 
the formation of undesired side products (Table VIII.1), the α-amino group of the amino acid 
to be acylated has to be masked only temporarily to allow further chain elongation. 
Frequently used temporary α-amino protecting groups in peptide chemistry are, in the order 
of their development, benzyloxycarbonyl (Cbz)2, tert-butyloxycarbonyl (Boc)3, 4 and 
fluorenyl-9-methoxycarbonyl (Fmoc)5, 6, the latter two being commonly applied in the 
automated SPPS. The Boc and Fmoc strategies differ in the removal of the respective α-
amino protecting group: while the Boc-group requires 50% TFA to be cleaved, the Fmoc-
group is cleaved under basic conditions (20-40% piperidine). The advantages of the Fmoc-
strategy compared to the Boc-strategy are: (i) exceptional acid stability, (ii) rapid 
nonhydrolytic deblocking by simple amines, (iii) compatibility with tert-butyl- and benzyl-
based systems, (iv) direct liberation of protected amine in the free base form and (v) facile UV 
or fluorescence monitoring of deblocking. 
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Table VIII.1. Recommended side-chain protecting groups in the Boc- and Fmoc-strategy.7 Those used in the 
presented work are underlined. 
 
Suitable protecting groups Amino acid 
Boc-strategy Fmoc-strategy 
Cys Acm, 4-MeBzl, 4-OMeBzl Acm, tBu, Trt
Asp Bzl, cHx tBu, MPe 
Glu Bzl, cHx tBu
His Dnp, Bom, Tos, Cbz Trt
Lys 2-Cl-Cbz Boc, ivDde, Mmt 
Asn -- Trt
Gln -- Trt
Arg Tos, Mts, NO2 Pmc, Pbf
Ser Bzl tBu
Thr Bzl tBu, Trt 
Trp For Boc
Tyr 2-Br-Cbz tBu, 2-ClTrt 
Ala, Phe, Gly, Ile, 
Leu, Met, Pro, Val 
unprotected unprotected 
 
 
Temporary side-chain protecting groups 
Besides the permanent protection of the amino acid side chains mentioned above, also 
temporary side-chain protecting groups can be applied, which are stable both at the conditions 
used for the removal of the other side-chain and α-amino protecting groups. One example is 
the methyltrityl (Mtt) protecting group for lysine which can be selectively removed with 1% 
TFA in the presence of 1% triisopropylsilane (TIS) and allows the preparation of branched 
peptides or the introduction of fluorescent labels. 
 
Total cleavage 
During the repetitive deprotection and coupling steps of the peptide synthesis, the 
linkage of the peptide to the resin has to be stable, while it has to be cleaved in the last 
synthesis step to release the fully synthesized peptide. The final cleavage usually requires 
harsh conditions like anhydrous HF or other strong acids in Boc-strategy and trifluoroacetic 
acid (TFA) in Fmoc-strategy. Conveniently, the side-chain protecting groups are chosen to be 
also cleaved under these conditions. During the cleavage highly-reactive electrophilic species 
are formed, including tert-butyl and trityl cations and the resin-bound linker itself. In order to 
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prevent the reattachment of these species to the peptide chain, nucleophiles like TIS, 
triethylsilane (TES) or water have to be added to the cleavage mixture as scavengers. 
 
 
VIII.2.1.2 Experimental procedure 
 
General procedure 
All peptides were prepared on a 0.018 mmol scale using Fmoc chemistry on Rink amide 
MBHA resin (loading 0.6 mmol g-1) on a Syro-I peptide synthesizer from MultiSynTech. The 
following side-chain protections were applied: tBu (Asp, Glu, Ser, Thr), Boc (Lys), Trt (Cys, 
His, Asn, Gln) and Pbf (Arg). Chain assembly was accomplished by a double coupling 
procedure (2 x 40 min) using Fmoc-amino acid/HOBt/HBTU/DIEA (5:5:5:10 equiv.) in 
DMF/NMP (70:30, v/v), followed by Fmoc removal with piperidine in DMF/NMP (80:20, 
v/v) (3 min with a 40% base solution plus 10 min with a 20% base solution). 
To monitor the progress of the synthesis, test cleavages using small amounts of resin were 
conducted and the resulting samples were analyzed by MALDI-ToF-MS and analytical HPLC. 
Final cleavage of the peptides from the resin and simultaneous side-chain deprotection was 
achieved by treatment of the peptidyl resin with 1.5 mL of a TFA/water/TIS mixture for three 
hours. For Met/Cys-containing peptides EDT was added to the cleavage cocktail. In all cases 
the ratio TFA/scavengers was 9:1 (v/v). The peptides were then precipitated from ice-cold 
ether, centrifuged and subjected to several ether-washing/centrifugation cycles to remove the 
scavengers. 
 
Mtt cleavage 
The Mtt protecting group used for the orthogonal side-chain protection of lysine and 
ornithine in the peptides III.5-III.9 was cleaved by washing the resin with a solution 
containing 1% TFA and 1% TIS in DCM (ten cycles). After each cycle the resin was washed 
with DCM. Finally, the resin was washed with DCM (5 x) and DMF (5 x). After washing 
with a 1.2 M DIEA solution, the resin was washed again with DMF, DCM and diethyl ether. 
During the preparation of peptide III.8 the Mtt cleavage resulted to be incomplete, which led 
to a truncated analog as a side-product (peptide III.9). 
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Methionine reduction 
Peptides that showed an oxidation of the methionine residue were treated with a 
reduction mixture consisting of TFA/TMSBr/EDT (95:2.5:2.5, v/v) for 1 h. Then, the peptides 
were precipitated from ice-cold ether and washed as described above. 
 
 
VIII.2.1.3 Preparative HPLC 
 
The synthesized peptides were purified by preparative RP-HPLC on a Phenomenex 
Luna C-18(2) column (10 µm, 250 × 21.2 mm). The crude products were dissolved in water 
or 20% acetic acid and filtered through polytetrafluoroethylene or polyvinylidene difluoride 
syringe filters. 0.004% (v/v) TFA in water (solvent A) and ACN (solvent B) were used as 
binary elution system. The gradient was 15% B for 5 min followed by 15-75% B over 66 min; 
the flow rate was 21 mL min-1. UV detection was done at 220 nm. 
After collecting the fractions and evaporating the ACN, the peptides were lyophilized. The 
pure products were characterized by analytical HPLC and mass spectrometry, as reported in 
the following. All peptides were obtained with purities higher than 93%. 
 
 
VIII.2.2 Oxidation experiments 
 
VIII.2.2.1 Monomer oxidation 
 
To produce the disulfide linked dimers IV.1OX and IV.2OX, the cysteine containing 
peptides IV.1 and IV.2 (1 mg each) were dissolved in 1 mL of degassed 0.1 M ammonium 
carbonate buffer (pH ~ 8) and allowed to oxidize under air atmosphere in an opened 
Eppendorf vial. To follow the course of the oxidation reaction, small aliquots were taken after 
0 h, 24 h, 48 h and 72 h, respectively, acidified by addition of 10 µL of 20% acetic acid and 
subjected to analytical HPLC and MS measurements. 
 
VIII.2.2.2 Thiol exchange assay 
 
Peptides IV.1 and IV.2 (1 mg each) were dissolved in 1 mL 0.1 M ammonium carbonate 
buffer (pH ~ 8) containing 20 mM reduced glutathione and 40 mM oxidized glutathione. 
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After 4.5 h, 22 h and 46 h small aliquots were taken, acidified with 10 µL 20% acetic acid and 
subjected to analytical HPLC and MS measurements. 
 
 
VIII.2.3 Peptide characterization 
 
VIII.2.3.1 Analytical HPLC 
 
For the analytical HPLC measurements a small amount of the peptide was dissolved in 
millipore water containing 0.1% TFA. The analytical RP-HPLC instrument consisted of the 
following parts: an L-6200A Intelligent pump from Merck, a HP detector series 1050 from 
Agilent and a Phenomenex Luna C-18(2) column (90 Å, 3 µm, 150 × 4.60 mm). The binary 
elution system consisted of 0.012% (v/v) TFA in water (eluent A) and 0.01% (v/v) TFA in 
ACN (eluent B). The following gradients were applied: 5% B for 3 min, 5-40% B over 40 min 
(peptides VI.8-VI.12) and 10% B for 3 min, 10-70% B over 40 min (remaining peptides).  
 
VIII.2.3.2 Mass spectrometry 
 
For the mass spectrometry measurements a small sample of the peptide was dissolved in 
0.1% TFA in millipore water and mixed with a solution of α-cyano-4-hydroxycinnamic acid 
in MeOH/ACN (1:1, v/v). The mass spectra were then recorded on a Future GSG 
spectrometer (Bruchsal, Germany) for MALDI-ToF-MS analysis. 
 
VIII.2.3.3 UV spectroscopy 
 
The concentration of the peptide samples prepared for CD and NMR measurements 
were determined UV spectrophotometrically on a Cary 100 Conc from Varian (Darmstadt, 
Germany) using 1 cm quartz cuvettes obtained from Hellma (Müllheim, Germany). By 
measuring the tyrosine absorption at 280 nm the concentration was calculated according to the 
Lambert-Beer law using an extinction coefficient of 1480 M-1 cm-1 per tyrosine residue. 
The ratio between the peptide concentration values obtained by UV and by weight gave the 
peptide content. In case of peptides lacking tyrosine or tryptophan residues the peptide 
contents of similar peptides containing these residues were applied to calculate the 
concentration. 
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VIII.2.4 Structural characterization 
 
As the biological action of peptides and proteins is determined by their structural 
properties, the conformational analysis of these biomolecules is a major goal in peptide and 
protein research. The most powerful methods for the structural characterization of peptides 
and proteins are FT-IR spectroscopy, CD spectroscopy, NMR spectroscopy and X-ray 
crystallography. While FT-IR and CD data provide insights in the presence or absence of 
secondary structure elements, the latter two allow a detailed description of the localization 
and spatial arrangement of such elements within the amino acid sequence. However, the 
advantage of the CD and FT-IR spectroscopy lie in the fast and simple way experiments can 
be conducted. Moreover, the influence of solvent, pH, ionic strength and temperature on the 
protein structure can be easily monitored. In the presented work the synthesized peptides have 
been characterized by CD and NMR spectroscopy. 
 
VIII.2.4.1 CD spectroscopy 
 
VIII.2.4.1.1 Introduction 
 
CD spectroscopy is based on the differential absorption of left and right circularly 
polarized light. To deliver a CD signal, a compound has to possess a chromophore, which is 
either inherent chiral or surrounded by a chiral environment and absorbs in the observed 
wavelength range. These prerequisites are met by the amide bond in peptides and proteins, 
rendering the CD spectroscopy a suitable methodology for the elucidation of their structural 
preferences. The observed bands in the CD spectra of peptides and proteins stem from the n 
→ π* and the π → π* transitions of the amide bonds.8 Every secondary structure gives rise to a 
specific CD spectrum that represents a survey upon the averaged overall structure of a peptide 
or protein and it is impossible to assign structural preferences to an individual residue (Figure 
VIII.1). However, algorithms based on protein and peptide reference data sets enable the 
calculation of the secondary structure elements composition of a peptide/protein from its CD 
spectrum. 
In addition to the far-UV region from 190-250 nm, also the near-UV region from 250 to 320 
nm can deliver useful information, as it shows the contribution of aromatic residues like 
tyrosine or tryptophan.9, 10 
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Figure VIII.1. CD spectra characteristic for common secondary structure elements (adapted from Greenfield11). 
 
The molar ellipticity [Θ]λ at the wavelength λ is defined as follows: 
 [ ] ⎥⎦
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λ Eq VIII.1 
 
where Ψ is the deviance of left- and right-circularly polarized light in degree, l the cell length 
in cm and c the peptide concentration in M. To compare peptides with different chain lengths, 
the molar ellipticity per residue is used, which is obtained by dividing [Θ]λ by the number of 
amino acids. 
 
Identification of interacting helices 
The CD bands characteristic for helical peptides at 190, 208 and 222 nm stem from the 
π → π* transition (190 nm and 208 nm are the components perpendicular and parallel to the 
helix axis, respectively) and n → π* transition (222 nm), with the latter being sensitive to 
hydrogen bond formation.12 The ratio R between the two minima at 222 and 208 nm can be 
used as an indicator for the presence of interacting helices, as the band at 208 nm, 
corresponding to the parallel component of the π → π* transition, changes its energy upon an 
interhelical interaction. Ratios larger than 1 are commonly regarded as the result of interacting 
helices, as found in coiled coil structures, while ratios lower than 1 indicate the presence of 
non-interacting helices.13 
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VIII.2.4.1.2 Experimental procedure 
 
All CD spectra were recorded at room temperature on a JASCO J710 
spectropolarimeter using a quartz cuvette with a path length of 0.02 cm. The peptide stock 
solutions were prepared in 0.1 M phosphate buffer (pH 7.3), and the concentrations were then 
determined UV spectrophotometrically. For each CD spectrum ten scans were accumulated 
using a step resolution of 1 nm, a bandwidth of 1 nm, a response time of 2 s, a scan speed of 
20 nm min-1 and a sensitivity of 10 mdeg, 20 mdeg or 50 mdeg, depending on the peptide 
concentration. To eliminate interferences which stem from cell, solvent and optical equipment, 
the CD spectrum of the buffer was subtracted from that of the peptide. The noise reduction 
was obtained by a Fourier transform filter using the program Origin (OriginLab Corporation, 
Northampton, USA). The obtained dichroic data were evaluated by using DICHROWEB14, 15, 
an online service for the evaluation of CD data. DICHROWEB relies on the five algorithms 
SELCON3, K2d, CDSSTR, VARSLC and CONTINLL16, 17; the latter one was used in 
combination with the reference dataset 718 for the CD analysis in the presented work. In all 
cases the analysis delivered a goodness-of-fit parameter RMSD that was below 0.13.  
 
 
VIII.2.4.2 NMR spectroscopy 
 
VIII.2.4.2.1 Introduction 
 
Together with the X-ray crystallography, the NMR spectroscopy is the method of choice 
for determining three-dimensional protein structures. Drawbacks in the applicability of NMR 
experiments are the required solubility of the samples in the necessary concentration range 
(~0.5-1 mM) as well as the stability of the sample during the measurements. Moreover, the 
structure determination can be hindered by the lack of constraints. Following the sample 
preparation, the recording of 2D-NMR experiments represents the second step towards the 
protein structure determination, as outlined in Scheme VIII.3.  
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Scheme VIII.3. Protein structure determination by NMR.19 
 
 
 
 
VIII.2.4.2.2 Sequential assignment 
 
The sequential assignment of an unlabeled peptide or small protein requires the 
combined information of the following 2D-NMR experiments: 
i) the cross peaks observed in the COSY spectrum correspond to proton-proton correlations 
due to scalar (through-bond) couplings, though the respective protons may only be separated 
by a maximum of three covalent bonds within the amino acid; 
ii) the TOCSY spectrum contains all correlations between protons of one spin system (Figure 
VIII.2). As there is no scalar coupling across the amide bond, every amino acid represents a 
single spin system; 
iii) the NOESY spectrum provides cross peaks from protons which are spatially close. As the 
TOCSY spectrum is limited to the observation of the single peptide units, the sequential 
connectivities have to be elucidated from the NOESY experiment. 
The sequential assignment usually starts by regarding the backbone NH-αH region of the 
COSY spectrum, which is considered a fingerprint of the corresponding protein. In this region 
every amino acid gives rise to a single cross signal. Exceptions are glycine, which shows two 
signals, and proline, which does not show any signal due to the absence of the NH proton. 
Counting the available COSY signals in this region rapidly assesses the quality of the NMR 
experiment in terms of spectral resolution and appearance. The next step is then the 
identification of the different spin systems in the TOCSY spectrum, which are lined up 
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vertically and correspond to the respective amino acids. The number of peaks per spin system, 
as well as their distribution is characteristic for every amino acid and can be used for the 
assignment. Finally, the necessary information about the sequential connectivities of amino 
acids is delivered by the NOESY experiment: a NOE signal from the NH of one amino acid to 
the αH of the following one indicates the connection of the two amino acids. 
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Figure VIII.2. Exemplary TOCSY NMR spectrum of a peptide. Important regions are marked in red. 
 
 
VIII.2.4.2.3 Chemical shift index (CSI) 
 
Once the sequential assignment of the protein has been obtained, the chemical shift 
index (CSI) method offers a rapid evaluation of the secondary structure present in the sample. 
The CSI approach was introduced 1992 by Wishart et al. and is based on the dependence of 
the chemical shifts of the α-protons on their surrounding environment, i.e. the secondary 
structure of the peptide or protein.20 The CSI value for every amino acid is obtained by 
subtracting reference values (obtained from a randomly structured protein) from the 
experimental α-proton chemical shifts. Four or more negative differences in a row indicate 
the presence of an α-helix, while a grouping of three or more positive differences are 
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commonly regarded as evidence for a β-strand. The remaining residues are designated to be 
randomly ordered. 
A comparison of the secondary structure content extrapolated by the CSI pattern with the one 
obtained from crystal structures of proteins showed that the results are strongly dependent 
upon the used reference values and only helices are estimated properly.21 Nevertheless, the 
data set by Schwarzinger et al.22 was found to be a good estimator of both helical and β-sheet 
structure content.  
 
 
VIII.2.4.2.4 NOE signals 
 
The 2D-NOESY (nuclear Overhauser effect spectroscopy) spectrum shows peaks 
stemming from nuclei that are close within the molecule, but not necessarily directly 
connected to each other. Therefore, the NOESY spectrum exhibits most or all peaks observed 
in the COSY spectrum and additionally shows cross signals from protons which are not 
neighboring in the sequence but close to each other in space (< 5 Å). The obtained strength of 
the NOE cross signals then directly relates to the distance r of the participating nuclei and is 
inversely proportional to r6. As the repetitive character of secondary structures in peptides and 
proteins gives rise to defined distances between the involved atoms, every structure element 
possesses a distinctive NOE “signature” and the NOESY spectrum can be used to identify the 
presence of these elements in the sample (Figure VIII.3 and Table VIII.2).  
 
 
Figure VIII.3. Observable NOE signals in polypeptides. 
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Table VIII.2. Characteristic NOE patterns in polypeptides.23 “−“ – no cross signals, “+” – weak to medium 
strength cross signal, “++” – strong cross signals observable. 
 
 β-sheet α-helix 310-helix 
dαN(i,i+4) − + − 
dαβ(i,i+3) − ++ + 
dαN(i,i+3) − ++ ++ 
dNN(i,i+2) − + + 
dαN(i,i+2) − − + 
dNN + ++ ++ 
dαN ++ + + 
 
In practice, the NOE signals not corresponding to sequential amino acids (i.e. the ones not 
used for the sequential assignment) are assigned and classified according to their strength in 
weak, medium and strong signals. By calibrating the NOE signals with signals of known 
distance (e.g. geminal, diastereotopic protons or aromatic protons positioned ortho to each 
other), useful constraints for structural calculations can be obtained. 
 
 
VIII.2.4.2.5 Experimental procedure 
 
The peptide reproducing the HLH motif of Id2 was dissolved in a mixture of 
H2O/TFE-d2 in a ratio of 40:60 (v/v) at a concentration of 0.5 mM. The NMR experiments 
were then recorded on a Bruker Avance 600 (600.13 MHz). A temperature scan from 300 K 
to 318 K in 6 K steps revealed the temperature of 318 K to be optimal for the experiments, as 
the least overlaps and sharper signals were observed in the NH region at this temperature. 
Consequently, all 2D measurements were conducted at this temperature. In the DQF-COSY, 
CLEAN-TOCSY and NOESY experiments the water resonance was suppressed by using the 
presaturation method. The mixing time accounted to 80 ms for the TOCSY and 200 ms for the 
NOESY experiment. The obtained data were processed using the TOPSPIN software 
purchased from Bruker (version 1.2). After the sequential assignment, the CSI pattern was 
calculated using the procedure developed by Wishart et al.20 
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VIII.2.5 Fluorescence spectroscopy 
 
VIII.2.5.1 Experimental procedure 
 
The fluorescence spectra were measured on a Cary Eclipse Spectrophotometer from 
Varian using a 1 cm path length quartz cuvette containing 1 mL of the receptor solution at a 
concentration of 9.5 µM in 50 mM HEPES buffer (pH 7.5). Small aliquots (5 µL up to 50 µL) 
of the peptide stock solution (64-142 µM in HEPES buffer) were added manually to the 
receptor solution. The excitation wavelength was 305 nm. The emission spectra were 
recorded over the range 310-500 nm using a bandwidth of 5 nm at a temperature of 25 °C. 
Fitting of the titration data was done by using the Hill equation24:  
 hh
h
cK
cFF +
⋅Δ=Δ
5.0
max  Eq VIII.2 
 
where h is the Hill coefficient, K0.5 the peptide concentration at which half of the receptor is 
bound, ΔFmax the fluorescence increment observed at saturation of the receptor and ΔF the 
observed fluorescence increment at the peptide concentration c. For the Job’s plot analysis25, 
26 two solutions with equal concentrations of the receptor and the peptide (c in the range from 
10 µM to 41 µM) were prepared and mixed to produce eleven different solutions 
corresponding to a receptor molar ratio increasing from 0 to 1. 
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IX  Appendix 
 
IX.1 Synthesized peptides – analytical data 
 
Table IX.1. Analytical data of the synthesized peptides. All peptides were N-terminally acetylated and C-
terminally amidated. All retention times were measured using the gradient 10% ACN for 3 min, 10-70% ACN 
over 40 min, except the ones marked with an asterisk which were measured using the gradient 5% ACN for 3 
min, 5-40% ACN over 40 min. 
 
No. Peptide MWcalc. (Da) MWfound (Da) tr (min) 
III.1 Ac-(66-106)-Id1 4930.61 4932.7 18 
III.2 Ac-[retro66-80, des81]-(66-106)-Id1 4833.00 4829.6 18 
III.3 Ac-[Ahx82-90]-(66-106)-Id1 4037.85 4036.8 19 
III.4 Ac-[retro66-80, des81, Ahx82-90]-(66-106)-Id1 3922.66 3922.1 18 
III.5 Ac-[Orn82-90]-(66-106)-Id1 4062.80 4066.2 18 
III.6 Ac-[retro66-80, des81, Orn82-90]-(66-106)-Id1 3964.65 3962.4 19.5 
III.7 Ac-(89-106)-βAlaLys(retro66-80)-Id1 4237.02 4239.7 20 
III.8 Ac-(89-106)-βAlaLys(66-83)-Id1 4549.40 4547.3 20 
III.9 Ac-(89-106)- βAlaLys-Id1 2408.85 2410 17 
III.10 Ac-[retro69-80, ProGly81-90]-(69-103)-Id1 3212.70 3215.2 18 
III.11 Ac-[F73, 101]-(66-106)-Id1 4898.81 4905 19.5 
III.12 Ac-[F101]-(66-106)-Id1 4914.81 4917.6 18 
III.13 Ac-[F73]-(66-106)-Id1 4914.81 4910.1 17.5 
IV.1 Ac-CGG-(66-106)-S72-GGG-Id1 5303.15 5299.5 16 
IV.2 Ac-(66-106)-S72-GGC-Id1 5132.00 5132.7 15.7 
VI.1 Ac-(36-76)-Id2 4906.85 4907.7 20.5 
VI.2 Ac-(41-81)-Id3 4838.60 4839.6 22.1 
VI.3 Ac-(65-105)-Id4 4896.82 4893.3 18 
VI.4 Ac-(66-82)-Id1 2042.40 2042.1 16.4 
VI.5 Ac-(41-56)-Id3 2058.36 2058.4 15.2 
VI.6 Ac-(65-80)-Id4 2109.45 2110.5 14.2 
VI.7 Ac-(89-105)-Id4 2067.43 2066.8 22.4 
VI.8 Ac-(72-75)-Id1 568.66 569.3 5 (*) 
VI.9 Ac-[A73]-(72-75)-Id1 476.56 477.0 3.5 (*) 
VI.10 Ac-[A72]-(72-75)-Id1 536.59 537.3 3.5 (*) 
VI.11 Ac-(42-45)-Id2 540.64 541.1 4 (*) 
VI.12 Ac-(67-72)-Id3 838.01 838.3 10.5 (*) 
VI.13 Ac-(122-160)-MyoD 4545.30 4531.4 19 
VI.14 Ac-(36-74)-Max 4576.17 4575.8 13.4 
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IX.2 CONTIN analysis of the CD data for the Id2 HLH motif 
 
 
Table IX.2. Results of the CONTIN analysis for the structural composition of the Id2 HLH motif in different 
solvent mixtures (c = 30 µM). nhelical – calculated number of helical amino acids, R – ratio between the ellipticity 
minima at 222 nm and 208 nm. 
 
Solvent helix β-strands turns unordered nhelical R 
water 49% 3% 13% 35% 20 0.88 
phosphate  buffer 0.1M pH 7.25 60% 8% 13% 19% 24 1.04 
water/TFE 40:60 (v/v) 72% 1% 12% 15% 30 0.74 
100 % TFE 91% 0% 9 % 0% 37 0.81 
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IX.3 NMR data of the Id2 HLH motif 
 
Table IX.3. The 1H chemical shifts (ppm) for the Id2 HLH motif (0.5 mM in water/TFE-d2 40:60 at 318 K). 
 
 NH αH β(β’) γ(γ’) δ(δ’) other 
Leu1 7.55 4.21 1.57 0.92 0.86  
Tyr2 7.44 4.49 3.06 (2.89)   Ring protons – 7.07, 6.85 
Asn3 8.12 4.77 2.88 (2.77)    
Met4 8.07 4.39 2.13 2.64 (2.57)   
Asn5 7.83 4.70 2.86 (2.73)    
Asp6 8.03 4.29 2.90 (2.97)    
Cys7 7.99 4.38 3.12 (3.16)    
Tyr8 8.16 4.64 2.88   Ring protons – 7.36, 6.59 
Ser9 7.92 4.63 4.04 (4.02)    
Lys10 7.67 4.23 1.92 1.48 (1.57) 1.73 ε – 3.01 
Leu11 7.83 4.16 1.80 1.64 0.91  
Lys12 7.74 4.10 1.83 1.46 1.68 (1.75) ε – 3.00 
Glu13 7.97 4.29 2.22 2.72 (2.63)   
Leu14 7.76 4.35 1.98 1.80 (1.65) 0.91  
Val15 7.65 4.26 2.18 1.01   
Pro16  4.47 2.30 (1.96) 2.08 3.62 (3.81)  
Ser17 7.86 4.50 3.94 2.01 (2.33) 2.12  
Ile18 7.76 4.24 1.80 1.65 0.99 γ2 – 1.22 
Pro19  4.41 2.33 (2.01) 2.12 3.75 (3.91)  
Gln20 8.11 4.26 2.06 (2.16) 2.44   
Asn21 8.17 4.65 2.81 (2.90)    
Lys22 8.16 4.25 1.92 1.48 (1.57) 1.73 ε – 3.01 
Lys23 7.93 4.21 1.93 1.46 (1.56) 1.76 ε – 3.03 
Val24 7.78 3.99 2.11 1.00 (1.03)   
Ser25 7.91 4.40 3.97 (4.10)    
Lys26 8.06 4.09 1.97 1.50 (1.63) 1.75 ε – 2.98 
Met27 7.60 4.33 2.20 2.54   
Glu28 7.07 4.38 2.20 (2.35) 2.52 (2.63)   
Ile29 7.91 3.80 2.07 1.16 0.86 γ2 – 0.96 
Leu30 8.19 4.11 1.84 1.80 0.96 (0.94)  
Gln31 8.28 3.95 2.12 (2.23) 2.35 (2.49)   
His32 7.87 4.38 3.45   
NH(Imidazole) – 9.65 
ε – 8.57 
δ – 7.31 
Val33 8.29 3.77 2.37 1.03 (1.12)   
Ile34 8.50 3.76 1.93 1.25 0.85 γ2 – 0.95 
Asp35 8.08 4.41 3.03 (2.85)    
Tyr36 7.94 4.33 3.37 (3.20)   Ring protons – 7.13, 6.81 
Ile37 8.30 3.66 2.10 1.30 0.89 γ2 – 0.94 
Leu38 8.51 4.13 1.92 1.51 0.88  
Asp39 8.01 4.55 2.97 (3.05)    
Leu40 7.89 4.18 1.77 1.54 (1.65) 0.80  
Gln41 7.84 4.22 2.09 (2.21) 2.45   
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IX.2 Fluorescence titrations 
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Figure IX.5. Titration curves of R1 (9.5 µM in 50 mM HEPES buffer, pH 7.5) with peptides III.1 (A), VI.1 (B), 
VI.2 (C) and VI.3 (D). Solid lines represent the fit of the experimental points preceding the loss of emission 
intensity. 
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